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Background: Mulibrey nanism (MUL; Muscle-liver-brain-eye nanism; OMIM 
253250) is an autosomal recessive growth disorder more prevalent in Finland 
than elsewhere in the world. Clinical characteristics include severe prenatal-
onset growth restriction, cardiopathy, multiple organ manifestations but no 
major neurological handicap. MUL is caused by mutations in the TRIM37 gene 
on chromosome 17q22-23, encoding a peroxisomal protein TRIM37 with ubiq-
uitin E3-ligase activity. Nineteen different mutations have been detected, four 
of them present in the Finnish patients. 
Objective: This study aimed to characterize clinical and histopathological fea-
tures of MUL in the national cohort of Finnish patients. 
Patients and methods: A total of 92 Finnish patients (age 0.7 to 77 years) par-
ticipated in the clinical follow-up study. Patients’ hospital records and growth 
charts were reviewed. Physical, radiographic and laboratory examinations were 
performed according to a clinical protocol. Thirty patients (18 females) were 
treated with recombinant human GH for a median period of 5.7 years. Biopsies 
and autopsy samples were used for the histopathological and immunohisto-
chemical analyses. 
Results: MUL patients were born small for gestational age (SGA) with imma-
ture craniofacial features after prenatal-onset growth restriction. They expe-
rienced a continuous deceleration in both height SDS and weight-for-height 
postnatally. In infancy feeding difficulties and frequent pneumonias were com-
mon problems. At the time of diagnosis (median age 2.1 years) characteristic 
craniofacial, radiological and ocular features were the most constant findings. 
MUL patients showed a dramatic change in glucose metabolism with increas-
ing age. While the children had low fasting glucose and insulin levels, 90% of 
the adults were insulin resistant, half had type 2 diabetes and an additional 
42% showed impaired glucose tolerance (IGT). Seventy percent fulfilled the 
National Cholesterol Education Program (NCEP) Adult Treatment Panel III crite-
ria for metabolic syndrome as adults. GH therapy improved prepubertal growth 
but had only minor impact on adult height (+5 cm). Interestingly, treated sub-
jects were slimmer and had less frequent metabolic concerns as young adults. 
MUL patients displayed histologically a disturbed architecture with ectopic tis-
sues and a high frequency of both benign and malignant tumours present in 
several internal organs. A total of 232 tumorous lesions were detected in our 
patient cohort. The majority of the tumours showed strong expression of en-
dothelial cell marker CD34 as well as α-smooth muscle actin (α-SMA). Fifteen of 




Conclusions: MUL patients present a distinct postnatal growth pattern. Short-
term response of GH treatment is substantial but the long-term impact remains 
modest. Although MUL patients form a distinct clinical and diagnostic entity, 
their clinical findings vary considerably from infancy to adulthood. While fail-
ure to thrive dominates early life, MUL adults develop metabolic syndrome and 
have a tendency for malignancies and vascular lesions in several organs. This 
speaks for a central role of TRIM37 in regulation of key cellular functions, such 




Finland was sparsely populated 10 000 years ago by few settlers of mostly 
unknown origin and remained so for thousands of years, mostly due to geo-
graphic reasons but also due to our language. Also, population-isolates dis-
tantly located from each other, often separated by large lakes or deep forests, 
were a common feature. This gradually resulted in loss of genetic variation due 
to marriages within the population. The occurrence of one mutation within 
this small founding population was followed by enrichment giving rise to a 
phenomenon known as the founder effect, where one single or only few mu-
tations are present in the majority of the affected individuals (Provine 2004). 
Today, 36 rare monogenic and mostly autosomal recessive disorders are over-
represented in the Finnish population. In many of these, the number of iden-
tified cases is greater in Finland than reported worldwide. Together these 
disorders are known as the Finnish disease heritage, with a disease spectrum 
extending to somewhat all branches of clinical medicine (de la Chapelle 1993, 
Norio 2003). Almost one third of them cause mental retardation, and many 
result in visual impairment or deafness. Also, congenital malformations, bone 
disorders and metabolic, neurological, or hematological diseases as well as 
multi-systemic syndromes are represented. A substantial part causes handicap 
and heavy burden to the patient and his or her family (Norio 2003). Over the 
years, several of these monogenic disorders have been characterized at the 
molecular level which has helped physicians and scientists to understand the 
pathophysiology behind common diseases. The heterogeneous nature of many 
common conditions, such as diabetes mellitus or cancer suggests that more re-
search attention should be focused on phenotypically homogenous subgroups 




Figure 1. Perheentupa’s steps showing the 36 rare disorders of the Finnish disease 
heritage. Thirty-two of them are autosomal recessive, two autosomal dominant, 
and two X-linked. Adapted from Norio et al 1973.
In the early 1970s doctors Perheentupa, Autio, Leisti, Raitta, and Tuuteri de-
scribed a new Finnish dysmorphic growth disorder (Perheentupa et al 1970, 
1973). The disorder was first entitled Perheentupa syndrome but later renamed 
Mulibrey nanism (MUL; OMIM 253250); an acronym comprising of muscle hy-
potonicity (MUscle), hepatomegaly (LIver), enlarged ventricles and cisternae 
of the central nervous system (BRain) and yellowish dots in the midperipheral 
area of the ocular fundi (EYe). The term nanism was adapted from Latin; mean-
ing dwarfism or short stature. For decades, clinical care and follow-up was cen-
tred to the University of Helsinki Children’s Hospital. This gave rise to unique 
clinical data collected for over more than thirty years, part of which has been 
analyzed in this study.
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3. REVIEW OF THE LITERATURE
    
3.1 Normal growth 
Growth can be defined as gain in size by increase in tissue mass. Growth is 
a combination of cellular hyperplasia (increase in cell number), hypertrophy 
(increase in cellular size) and apoptosis (controlled cellular death). Successful 
growth is a well suited combination of these three tightly controlled cellular 
events (Clayton and Gill 2001). Optimal environment and interaction will allow 
a fertilized egg to develop into a mature human being, whereas disruptions 
may interfere with the developmental process and result in variable degrees of 
whole-body or regional growth restriction (Clayton and Gill 2001). 
Normal growth consists of four different stages; intrauterine, infant, childhood 
and pubertal growth, eventually resulting in adult stature (Figure 2) (Karlberg 
et al 1987a, Karlberg et al 1987b, Karlberg 1989, Clayton and Gill 2001). To 
achieve normal stature all these stages need to be successful. However, the 
control of growth is related to several complex interacting factors within the 
cell (intrinsic factors; i.e. genotype, epigenetic factors), or extrinsic factors (i.e. 
nutrition, environment, hormones and growth factors). Also, tissue growth will 
not end in all organ systems when the adult height is achieved and some cells 
maintain their capacity to proliferate, as is the case in the liver and endocrine 
tissues (Clayton and Gill 2001). 
Figure 2. The ICP model of growth. 
Postnatal growth is modelled as a 
combination of three components; 
1) rapid infant growth sharing fea-
tures with the intrauterine growth, 
2) steady childhood growth mainly 
regulated by GH and 3) the pubertal 
growth spurt driven by sex steroid 
hormones eventually resulting in 
adult stature. Adapted from Karlberg 
1989. 
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3.1.1 Prenatal growth
Intrauterine growth is a complex, dynamic process where cell proliferation, 
differentiation, and migration together form the developing organ systems 
of the fetus (Clayton and Gill 2001, Bryan and Hindmarsh 2006, Maulik et al 
2006a). During the first trimester of the pregnancy, tissue patterns and organ 
systems are forming from the three germ layers (ecto-, meso- and endoderm). 
Particularly rapid growth is seen between the gestational weeks 4 and 8 when 
all the major organ systems in the body are established. In the second trimes-
ter, the fetus undergoes cellular hyperplasia and rapidly increases in size. In the 
third trimester, the organ systems mature and the fetus is being prepared for 
extrauterine life (Clayton and Gill 2001).
Human growth hormone (GH) appears to have very little impact on prenatal 
growth, since individuals with complete GH deficiency or insensitivity display a 
nearly normal body size at birth (Rosenfeld et al 1994). Insulin, however, is the 
major growth mediator in utero affecting both intrauterine growth and size 
at birth, as seen in macrosomic infants born to diabetic mothers and in babies 
with congenital hyperinsulinism (Fournet et al 2004, Hadden 2008). Further, 
the importance of insulin-like growth factors (IGF-1 and IGF-2) in normal intra-
uterine growth has been established in some extraordinary case reports; one 
patient with a homozygous deletion of the IGF-1 gene (Woods et al 1996), one 
patient with mutated IGF-1 gene resulting in ineffective IGF-1 (Walenkamp et 
al 2005), and two patients with mutated IGF-1 receptor (Abuzzahab et al 2003), 
all displaying severe intrauterine growth restriction. Also mouse models with 
IGF-1 and IGF-2 deficiency have displayed restricted intrauterine growth (Accili 
et al 1999). 
IGF-1 influences the growth both pre- and postnatally, whereas IGF-2 only 
appears to regulate growth in utero. During fetal growth the IGF-2 effect is 
mediated through the insulin receptor (Nakae et al 2001). Interestingly, im-
printed genes at chromosome 11p15.5 have been associated with fetal growth 
(DeChiara et al 1990, Rossignol et al 2006). Genes in this cluster include the IGF2 
gene, and recent observations show hypomethylation of the imprinting con-
trol region (ICR) in some individuals with Silver-Russell syndrome (SRS; OMIM 
180860) (Bruce et al 2009), a dysmorphic growth disorder with prenatal-onset 
growth restriction. Interestingly, opposite epigenetic mutations of the same 
locus result in the overgrowth syndrome Beckwith-Wiedemann (BWS; OMIM 
130650), characterized by macrosomia, macroglossia, omphalocele, hemihyper-
plasia, peculiar external ears and a tendency for tumours in childhood (Gaston 
et al 2001, Eggermann et al 2008). As expected from these epigenetic findings, 
SRS and BWS subjects also display opposite tissue expression of IGF-2 (Girquel 
et al 2005, 2008, Eggermann et al 2008). Analysis of tissue samples from pa-
tients with BWS revealed overexpression of IGF-2 (Weksberg et al 2003), while 
lower IGF-2 expression was evident in SRS subjects (Girquel et al 2005).
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3.1.2 Postnatal growth
During the first year the human baby grows rapidly in length and weight, al-
though the growth rate is sharply decelerated in comparison with the intrau-
terine growth rate (Karlberg et al 1987a, Clayton and Gill 2001). This early post-
natal growth is strongly influenced by nutritional intake and the hormones 
primarily regulating growth are similar to those involved in the intrauterine 
growth (Euser 2008, Maulik et al 2008a). At this stage the correlation between 
height and weight and mean parental size is poor (Rosenthal and Wilson 1994). 
When the intrauterine effect gradually fades and vanishes normally by the age 
of 2.0 years, the infant establishes his or her own growth pattern (Clayton and 
Gill 2001). Somewhere between 6-12 months of age the secretion of the 191 
amino acid 22-kD human GH from the anterior pituitary gland (Lewis et al 
1980) starts to increase and as the infant grows into childhood, GH becomes 
the dominant moderator of growth (Albertsson-Wikland and Rosenberg 1988, 
Clayton and Gill 2001). 
The GH release is controlled by a balance between stimulatory growth hor-
mone releasing hormone (GHRH) and inhibitory somatostatin both from the 
hypothalamus (Rosenbloom and Connor 2007). This balance is regulated by 
neurological, metabolic (i.e. glucose, amino acids, free fatty acids), and hor-
monal (estrogen and testosterone) influences, as well as sleep (Strobl and 
Thomas 1994). After release, GH exerts its effects on target tissues by binding 
to the GH-receptor (GHR), which activates an intracellular cascade resulting in 
enhanced gene transcription (de Vos et al 1992). The biological actions of GH 
can only be reached in the presence of a normal function of the GHR and an 
optimal intracellular signalling pathway (Laron 2004). Deletions and mutations 
in the extracellular domain of the GHR gene result in GH insensitivity known 
as Laron syndrome (LTD; OMIM 262500) (Laron et al 1968). The typical features 
of Laron syndrome are short stature, characteristic face, obesity, acromicria, 
hypoglycemia, high basal serum GH, and low-serum IGF-1 unresponsive to the 
administration of exogenous GH (Laron 2004). Most of the growth effect of GH 
is a result of increased expression of IGF-1 in peripheral tissues, particularly in 
the liver and epiphyseal cartilage of long bones (Jones et al 1995, Walenkamp 
and Wit 2006).
IGF-1 and IGF-2 are single chain polypeptide hormones with considerable struc-
tural homology to insulin and share common structures of receptors and post-
receptor cascades (Rinderknech and Humble 1978, Nakae et al 2001). Indeed, 
IGFs can bind with a weaker affinity directly to the insulin receptor. IGFs are 
expressed in several tissues both under endocrine and paracrine regulation. 
Their actions on postnatal growth are mediated primarily by IGF-1 through its 
IGF-1 receptor (Jones et al 1995, Klammt et al 2008) and only to a lesser extent 
through the IGF-2 receptor (Nakae et al 2001). The expression of IGF-1 is con-
trolled by many factors other than GH. For instance, nutrient deficiency and 
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hypoxia both decrease the IGF-1 gene expression and synthesis (Rosenbloom 
and Connor 2007). Also, insulin has growth promoting effects and it stimulates 
the IGF-1 synthesis. IGF-1 possesses insulin-like metabolic actions, such as in-
creased uptake of glucose and fatty acids (Boulware et al 1992). Unlike insulin, 
the IGFs form complexes together with insulin-like growth factor binding pro-
teins (IGFBPs). The most important of these binding proteins is IGFBP-3, which 
is increased both by GH and also directly by IGF-1 (Jones et al 1995, Klammt et 
al 2008). IGFBP-3 and IGF-1 bind together with a third glycoprotein, the acid 
labile subunit (ALS), to form a stable 150 kDa ternary complex that serves as 
an intravascular store for IGFs and prolongs their life-span in the bloodstream 
(Donaghy et al 1996, Limal et al 2006). Reduced levels of ALS has been implicat-
ed in growth impairment for instance in some patients with Noonan syndrome 
(Limal et al 2006).
GH is the major determinant of growth during childhood. At this particular time 
dysfunctions in pituitary GH release, GH-receptor signalling and GH-IGF-1 axis 
are usually diagnosed (Albertsson-Wikland and Rosenberg 1988, Rosenbloom 
and Connor 2007). GH deficiency can be congenital, as in genetic defects and 
syndromes affecting the hypothalamic-pituitary axis or acquired (i.e. tumour, 
trauma and asphyxia) (Bunin et al 1998). The thyroid hormones also play an im-
portant role in the control of childhood growth, and are like GH strictly under 
hypothalamic regulation. Thyreotropin releasing hormone (TRH) is secreted 
into the hypophyseal portal system, resulting in release of thyroid stimulating 
hormone (TSH) from the anterior pituitary gland (Morley 1981). Downstream 
TSH stimulates the thyroid gland to synthesize and secrete thyroid hormones 
(T3 and T4). A close interaction between GH and thyroid hormones also exists. 
In the presence of hypothyroidism the pituitary GH secretion is subsequently 
diminished and the growth usually decelerates dramatically (Rosenbloom and 
Connor 2007).
Childhood growth is highly sensitive to environmental factors and depend-
ent on normal hormonal and metabolic functions (Albertsson-Wikland and 
Rosenberg 1988). Glucocorticoid excess or deficiency and diabetes mellitus all 
influence negatively on growth (Clayton and Gill 2001). Moreover, chronic dis-
eases such as gastroenterological, renal, cardiopulmonary, hematological dis-
orders and cancer may decelerate growth. Also infections and use of certain 
drugs, such as corticosteroids for asthma, may deprivate growth. Lack of vita-
min D, or minerals (e.g. phosphate, zinc and iron) and general malnutrition 
are still leading causes of growth deceleration or restriction in the third world 
countries. Psychosocial factors and stress can also be sources or worsening fac-
tors of growth deprivation (Clayton and Gill 2001).
In late childhood, additional hormonal changes occur (Cianfarani 2001). The 
adrenal glands begin to produce androgens from cholesterol and the gonads 
start to secret male or female sex hormones (testosterone and estrogen) under 
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hypothalamic control (Cutler 1997). Of the sex steroids, estrogen is the main 
determinant of pubertal growth in both sexes (Cutler 1997). This accelerates 
linear growth at the cartilage growth plates at the end of the diaphysis of 
long bones and the secondary sexual characteristics start to develop (Tanner 
and Whitehouse 1979, Cutler 1997). The pubertal growth displays an increased 
tempo (pubertal spurt) in growth, which usually reaches its peak velocity at 
Tanner stage 3 and 4 in girls and boys, respectively (Tanner and Whitehouse 
1979). The pubertal spurt is determined both by GH and sex steroids (Aynsley-
Green et al 1976, Karlberg et al 1987b, Kerrigan and Rogol 1992, Cutler 1997, 
Clayton and Gill 2001). The elevated levels of sex steroid hormones over time 
convert the cartilage cells into bone cells terminating the linear growth even-
tually resulting in adult stature (Cutler 1997, Clayton and Gill 2001). 
There is a large variation in human height and even fairly unusual growth 
patterns can be regarded as normal. However, the stature is considered ab-
normally short when the height standard deviation score (SDS) is 2.5 below 
the mean height for age and gender or mid-parental height (Rosenthal and 
Wilson 1994). An important cause resulting in short adult stature is early on-
set of puberty, in which maturation of bone is accelerated resulting in earlier 
growth arrest and short adult stature. In familial short stature the children 
are short primarily because their parents are short. Temporarily slow growth 
with catch-up growth compensating for final height is typical for late-onset 
puberty (Bhangoo et al 2007). Despite the abundance of different etiologies 
such as nutritional deprivation, hypothyroidism, pharmacological administra-
tion of glucocorticoids or mutations in the GH receptor, up to one fifth of sub-
jects with short adult stature remain without explanation for their restricted 
growth (Bhangoo et al 2007, Wit et al 2008a, 2008b). 
3.2 Intrauterine growth impairment
Intrauterine growth restriction (IUGR) is defined as growth impairment in 
utero, in which infants do not reach their genetic growth potential due to 
various genetic and/or environmental influences during gestation (Ergaz et al 
2005, Maulik et al 2006b). IUGR is especially important because of the higher 
incidence of morbidity and mortality and the potential for long-term compli-
cations in childhood. Newborns with IUGR face challenges like hypothermia, 
pulmonary hemorrhage, and life-threatening hypoglycemia more frequently 
compared to normal sized newborns (Cunningham et al 1997, Lee et al 2003a, 
Maulik et al 2006b). It has been estimated that an abnormal fetal karyotype 
would be responsible for about 20% of all intrauterine growth restricted fe-
tuses (Snijders et al 1993, Kinzler et al 2008).  
The term IUGR has been proposed to be limited to the process of compromised 
intrauterine growth rate detected by several ultrasonographic measurements. 
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If prolonged or severe enough it will lead to the delivery of a small for gesta-
tional age (SGA) infant. Early onset growth restriction is defined as clinically 
evident growth retardation before the completion of the 28th week of gesta-
tion (Wit et al 2006, Kinzler et al 2008). 
Figure 3. Schematic presentation of normal intrauterine growth, intrauterine growth restric-
tion (IUGR), small (SGA), appropriate (AGA) as well as large for gestational age (LGA).  
  
3.2.1 Small for gestational age
At birth, the newborn can have an appropriate weight and/or length for ges-
tational age (AGA), be large for gestational age (LGA) or small for gestational 
age in weight and/or length (Battaglia and Lubchenco 1967). Of all newborns, 
2.5% are born SGA. Traditionally, SGA refers to an infant with a birth weight 
below the 10th percentile for the gestational age. Among pediatric endocrinol-
ogists SGA is defined as birth weight and/or length more than 2.0 SD below 
the mean for gestational age (Figure 3) (Lee et al 2003b). Among SGA infants 
three subgroups can be distinguished; those with low weight but normal 
length (SWGA), those with short length but normal weight (SLGA) and infants 
with a combination of both low weight and short length for gestational age 
(SLWGA) (Albertsson-Wikland and Karlberg 1994, Karlberg and Albertsson-
Wikland 1995). 
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3.2.2 Low birth weight 
Small size at birth can also be determined according only to the weight at 
birth. WHO (World Health Organization) defines “low birth weight” as below 
2500 g. About 15 % of all infants are born with low birth weight. The level in 
developing countries is twice as high compared to developed regions (WHO 
statistics 2005). The term “low birth weight” is used irrespective of the gesta-
tional age and includes babies born prematurely and subjects with monogenic 
disorders, as well as familial or sporadic syndromes (Saenger et al 2007).
3.2.3 Factors influencing intrauterine growth
The intrauterine growth is controlled and influenced by a large quantity of 
both genetic and environmental factors of maternal, placental or fetal origin 
(Table 1) (Bryan and Hindmarsh 2006, Maulik et al 2006a, Saenger et al 2007). 
A significant portion (30-40%) of maternal factors is caused by hypertensive 
disorders of various etiologies. (Maulik et al 2006a). For instance, pre-eclampsia 
is associated with a 4-5 fold risk of delivering a SGA baby (Maulik et al 2006a). 
Other maternal factors leading to prenatal growth retardation include expo-
sure to toxic substances, chronic diseases, malnutrition, birth order, multiple 
births and maternal genetic factors, size and age (Table 1) (Wollmann 1998, 
Bryan and Hindmarsh 2006, Maulik et al 2006a, Saenger et al 2007). Sometimes 
several factors overlap, such as chronic malnutrition, tobacco smoking, alcohol 
abuse and low socioeconomic status which can result in, for instance, the fetal 
alcohol syndrome (FAS) (Gluckman and Hanson 2004, Kleijer et al 2005). FAS is 
characterized by IUGR, microcephaly and immature facial features, as well as a 
high frequency of gross organ anomalies, most commonly heart malformations 
(Kleijer et al 2005). Congenital heart disease is seen in approximately 20% of 
Finnish FAS children (Autti-Rämö et al 2006).  
The placenta is the life-line between the mother and the fetus and has an 
important role also in normal fetal growth. The growing fetus is vulnerable 
to nutrient deprivation and even mild placental dysfunction may restrict the 
transfer of nutrients and oxygen to the fetus so that growth deprivation grad-
ually occurs (Miller et al 2008). Placental dysfunction can be a consequence 
of metabolic disturbances or vascular damage (i.e. placental infarction), par-
tial placental separation, or simply a small placenta (Table 1) (Wollmann 1998, 
Bryan and Hindmarsh 2006, Maulik et al 2006a, Saenger et al 2007). 
Chromosomal aberrations are a well-established cause behind restricted fetal 
growth and are estimated to account for approximately 20% of cases (Snijders 
et al 1993, Kinzler et al 2008). The presence of polyhydramnion, nuchal-fold, 
structural malformations, elevated α-fetoprotein and small fetal size may be 
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indicative of chromosomal ab-
normality (Kinzler et al 2008). 
Uniparenteral disomy, inheritance 
of both homologes of a chromo-
some from a single parent, has 
also been associated with growth 
restriction in utero (Hannula et al 
2001).
Multiple fetal organ malforma-
tions are also associated with an 
increased risk of growth restriction 
in utero. The heart and abdominal 
wall are the organs most frequent-
ly affected (Table 1). Endocrine 
dysfunction as well as intrauterine 
infections particularly during criti-
cal times of organ development, 
are fetal factors behind restricted 
intrauterine growth and account 
for approximately 5-10% of cases 
(Rosenthal and Wilson 1994, Ergaz 
et al 2005). Bacterial infections 
only rarely compromise the intrau-
terine growth (Maulik et al 2006a). 
Premature birth has been associ-
ated with intrauterine growth re-
tardation for decades (Tamura et al 
1984). Also, gestations of multiple 
fetuses challenge the maternal sys-
tem to provide an optimal environ-
ment for growth. The incidence of 
SGA in twins is 15-30% and multi-
ple gestations account for nearly 
5% of all cases with intrauterine 
growth restriction (Maulik et al 
2006a, Kinzler et al 2008). 
3.2.4 Symmetric or asymmetric IUGR
Prenatal growth restriction can be classified according to its severity or by 
the effects on body proportions (i.e. symmetric or asymmetric) (Dasche et al 
2000, Maulik et al 2006b). Symmetrical restriction is usually due to fetal causes 







Table 1. Factors influencing intrauterine growth 
_________________________________________ 
Maternal factors 
   Maternal hypertension 
      Pre-eclampsia 
      Secondary hypertension 
   Renal disease 
   Gestational diabetes mellitus 
   Autoimmune disorders 
      Antiphospholipid syndrome, SLE 
   Thrombophilia 
   Cyanotic heart disease 
   Severe asthma 
   Anemia 
   Malignancy 
   Antepartum hemorrhage 
   Phenylketouria 
   Uterine anomalies 
      Large sub-mucous myomas 
      Uterus septae 
      Uterine fibroids 
   Life style 
      Smoking 
      Substance abuse; alcohol and drugs 
   Therapeutic agents and medications 
   Malnutrition 
   Low maternal weight gain and pregnancy BMI  
   Delivery at age < 16 or > 35 years 
   Environmental problems 
      Pollutions and toxic substances 
      High altitude 
      Low socioeconomic status 
Placental factors 
   Placenta praevia 
   Placenta accreta 
   Abruptio placentae 
   Circumvallate placentae 
   Placental infarction 
   Placental hematoma 
   Placental hemangioma 
   Placental vascular malformation 
   Confined placental mosaicism  
Fetal factors 
   Chromosomal abnormalities 
      Trisomy 13, 18 and 21 
   Genetic imprinting and uniparenteral disomy 
   Inborn errors of metabolism 
   Malformations 
      Heart; VSD, tetralogy of Fallot 
      Abdominal wall; gastroschisis, omphalocele, 
                                diaphragmatic hernia 
   Preterm birth 
   Multiple gestation 
   Infection; rubella, CMV, HIV, varicella zoster, 
                   herpes simplex, toxoplasmosis 
   Unexplained elevation of α-fetoprotein 
_________________________________________ 
Adapted from Maulik et al 2006a, Bryan and Hind-
marsh 2006, Saenger et al 2007 
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ciency. Asymmetrical restriction on the other hand, is mainly caused by extrin-
sic factors, for example, placental insufficiency or teratogenic substances. Also 
genetic syndromes and malnutrition might result in asymmetry of different 
organ systems, when the fetus tries to prioritize nutrition to certain organs, 
namely the brain but also heart and kidney, to maintain normal growth or 
development (Cunningham et al 1997, Maulik et al 2006b). For instance, small 
head circumference for gestational age can be indicative of severe or early 
intrauterine growth restriction (Euser et al 2008), chromosomal aberrations, 
environmental factors (i.e. toxic substances and intrauterine infections) or a 
consequence of IGF-1 dysfunction (Walenkamp and Wit 2006), while in a part 
of the growth restricted conditions spared cranial growth with normal head 
circumference can be observed (Hannula et al 2001, Huber et al 2005, Bruce 
et al 2009). Microcephaly, defined as occipitofrontal head circumference (OFC) 
below 2.0 SDS for age and sex, is associated with a poorer mental capacity and 
frequently neurological handicap (Abuelo 2007). 
3.3 Catch-up growth
Most (>70%) healthy SGA children show sufficient catch-up growth, usually 
beginning 2-3 months after birth, normalizing their stature commonly by the 
age of 2.0 years (Albertsson-Wikland et al 1998). This occurs especially in cases 
when the intrauterine growth has been restricted due to environmental factors. 
When these factors are removed after birth, the linear growth rapidly starts to 
normalize. Growth in very preterm infants, however, typically decelerates after 
exposure to extrauterine life, when their energy expenditure shifts to promote 
survival rather then growth (Gibson 2003, 2007, Euser et al 2008). However, ap-
proximately 10-15% of SGA children do not exhibit sufficient catch-up growth 
and remain persistently short throughout life (Albertsson-Wikland et al 1998). 
3.4 Consequences of being small at birth
Understanding intrauterine and early childhood growth has assumed great 
importance since epidemiological observations firmly show a link between in-
trauterine and early extrauterine growth restriction and risk of chronic adult 
disease, such as cardiovascular disease and type 2 diabetes (Barker 1995). It is 
estimated that one-third of SGA children will eventually develop insulin resist-
ance (Levy-Marchal et al 2004) and despite normal postnatal catch-up growth, 
they are still as adults prone to developing coronary heart disease, hyperten-
sion, type 2 diabetes (Barker et al 1993, Barker 1995, 1996) and metabolic syn-
drome (Veening et al 2003). 
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The entity metabolic syndrome was first described by Gerald Reaven as “syn-
drome X” in 1988. In the original description obesity was not included in the 
criteria (Reaven 1998). Today metabolic syndrome is defined as a constellation 
of glucose dysregulation, abdominal obesity, atherogenic dyslipidemia and hy-
pertension. Various health organizations (World Health Organization (WHO), 
International Diabetes Federation (IDF) and National Cholesterol Education 
Program (NCEP) have all established their own guideline definitions. All of 
them include this cluster of risk factors and are quite similar in their cut-off 
levels for triglycerides, high-density lipoprotein and blood pressure. However, 
their definitions of obesity and glucose intolerance differs (Table 2) (Alberti 
and Zimmet 1998, NCEP 2001, Alberti et al 2005). In 2001, the NCEP Adult 
Treatment Panel III (ATP III) devised a definition for the metabolic syndrome 
(NCEP 2001, Fedder et al 2002), which was updated in 2005 by the American 
Heart Association and the National Heart Lung and Blood Institute (Grundy et 
al 2005). The NCEP ATP III definition form one of the most widely used criteria 
of metabolic syndrome (Table 2). 
3.4.1 “The thrifty phenotype”
In the early 1980s, epidemiologist David Barker and colleagues investigated 
mortality rates for coronary heart disease and other vascular diseases in England 
and Wales. They noted that the highest rates occurred in areas associated with 
relatively high unemployment and low socioeconomic status and that the rates 
of heart disease were closely associated with the distribution of infant mortal-
ity. David Barker suggested that coronary heart disease might have its origin 
in early or intrauterine life and that poor nutritional conditions in a pregnant 
mother might modify the organ development of her unborn child so that the 
fetus will be programmed for survival in an environment short of resources 
(Figure 4) (Barker 1995, Hales and Barker 1992, 2001).
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Table 2. Definitions for metabolic syndrome 
___________________________________________________________________________________________________ 
NCEP IDF WHO 
___________________________________________________________________________________________________ 
Three of the following: Waist circumference  
     men  ≥94cm, women  ≥80cm 
Insulin resistance* (IGT, IFG, T2DM 
or other evidence of IR) 
   
Fasting plasma glucose ≥ 5.6mmol/l and at least two of the following and at least two of the following 
Waist circumference 
     men ≥102cm, women ≥88cm 
  
Triglycerides ≥1.7mmol/l Fasting plasma glucose  ≥5.6mmol/l   WRH** men >0.90, women >0.85 
 or BMI*** >30kg/m
2
 
HDL-cholesterol, men ≤1.0mmol/l, 
women ≤1.3mmol/l 
Triglycerides  ≥ 1.7mmol/l Triglycerides ≥ 1.7mmol/l 
 or HDL-cholesterol ≤0.9mmol/l 
Blood pressure  ≥130/85mmHg  
or medication 
HDL-cholesterol, men ≤1.0mmol/l, 
women ≤1.3mmol/l 
Blood pressure  ≥140/90mmHg 
or medication   
 Blood pressure  ≥130/85mmHg  
or medication     
Microalbuminuruia  
___________________________________________________________________________________________________ 
*IGT, impaired glucose tolerance; IFG impaired fasting glucose; T2DM, type 2 diabetes; IR, insulin resistance. **WHR; waist-
hip ratio, BMI***; body mass index.   Urinary albuminexcretion of ≥20ug/min or albumin-to-creatinine ratio of ≥ 30mg/g.   
Adapted from Alberti and Zimmet 1998, NCEP  2001, Fedder et al 2002, Grundy et al  2005, Alberti et al 2005. 
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Figure 4. The original presentation of the “thrifty phenotype hypothesis” by Hales 
and Barker 1992
The etiologies of type 2 diabetes and cardiovascular disease are multifacto-
rial and believed to arise from complex interactions between environmental 
and polygenic factors (Barker 1995, Jaquet et al 2000, Hales and Barker 2001, 
Cianfarani et al 2001). Today, many human diseases in adulthood are associ-
ated with poor growth in early life, suggesting early-life nutrition as the key 
mechanism. The “thrifty phenotype hypothesis” implicates that some meta-
bolic adaptations occur early in life to promote survival by selecting an appro-
priate growth pattern in response to the given environment. Individuals with 
the thrifty phenotype are proposed to have a lowered metabolic rate and a 
smaller body size and be especially prone to develop obesity or type 2 diabetes 
in an affluent environment (Hales and Barker 1992, 2001), whereas those who 
have experienced a positive fetal environment will more likely adapt to good 
conditions and therefore are better able to cope with the rich diets of today 
(Barker 1995, Hales and Barker 1992, 2001).
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The “thrifty phenotype” hypothesis has been challenged, but increasing 
amounts of evidence from different populations predict the same association 
(Eriksson 2001). However, alternative explanations to this association have also 
been suggested. For instance, low birth weight, impaired glucose tolerance, 
type 2 diabetes, and hypertension have all been suggested to be phenotypes 
of the same insulin-resistant or “thrifty” genotype (Hattersley and Tooke 1999, 
Frayling and Hattersley 2001). Further, insulin secreted by the fetal pancreas in 
response to maternal glucose concentrations has been shown as a key growth 
factor in utero (Fournet et al 2004). Monogenic diseases with impaired glucose 
sensing, lower insulin secretion or increased peripheral insulin resistance have 
been shown to manifest with impaired fetal growth (Hattersley and Tooke 
1999, Frayling and Hattersley 2001).
Also, the IGF-system has been suggested to play a part in the early program-
ming of metabolic consequences. Growth deceleration in utero and deprivated 
catch-up in early postnatal growth have been proposed to induce peripheral 
insulin resistance by increasing the amounts of peripheral IGF-1 receptors. This 
is proposed to promote faster growth but later predispose individuals to insu-
lin resistance or type 2 diabetes (Cianfarani et al 1999, 2001). 
3.5 Dysmorphic growth disorders
Failure to thrive is a condition where an infant is growing slower than ex-
pected with a concurrent poor weight progression. These patients are impor-
tant to be recognized early since the deceleration in growth can be a sign of 
an underlying chronic disease such as an endocrine dysfunction (i.e. growth 
hormone deficiency or hypothyroidism) or problems like inadequate nutrition, 
recurrent infections or abnormal behaviour affecting food intake. However, 
growth retardation or failure to thrive can also be an early sign of an enduring 
congenital disorder (Clayton and Gill, Ergaz et al 2005). 
A strong association between chromosome aberrations, IUGR and congenital 
malformations exists (Monk and Moore 2004). For example, fetuses with triso-
mies are frequently growth restricted. Children with Down’s syndrome (trisomy 
21; OMIM 190685) display postnatal growth retardation and later short adult 
stature (Cronk et al 1988). Also, many chromosome abnormalities include sub-
optimal growth of the fetus as one of the major hallmarks. In Turner syndrome 
(TS) the girls have sex chromosome abnormalities, either pure 45X or 46XX 
with aberrant X chromosome or mosaicism. The most frequent clinical finding 
in Turner syndrome is short stature, which has strongly been associated with 
dysfunction of the Short Stature Homeobox-containing gene (SHOX) on chro-
mosome Xp22.33 (Sybert and McCauley 2004).
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Several congenital disorders also present growth failure, typically with lack 
of catch-up in growth. A significant portion of them occur due to abnormal 
growth and remodelling of bone or cartilage (Baitner et al 2000). Over 250 
different types of skeletal dysplasias are known (Alanay et al 2007). These dis-
orders, generally referred to as chondro- or osteochondrodysplasias, are he-
reditary conditions with mutations for example in fibroblast growth factor 
receptors, collagens, different hormone receptors or sulphate transporters un-
derlying them (Baitner et al 2000, Cohen 2002a). These disorders manifest with 
short stature and disproportionately short extremities as major clinical signs 
and often include other features that will require medical attention (Baitner 
et al 2000). Diastrophic dysplasia (DTD; OMIM 222600) and cartilage-hair hy-
poplasia (CHH; OMIM 250250) are congenital bone and cartilage disorders be-
longing to the Finnish disease heritage (Norio 2003).
Another category is genetic or monogenic syndromes characterized by growth 
restriction, short adult stature and dysmorphic craniofacial and constitutional 
features (Cohen 2002b) (Table 2). Several of them also manifest with a vari-
ous degree of mental retardation. For instance, Prader-Willi syndrome (PWS; 
OMIM 176270), which is characterized by growth failure, mental deficiency, 
hyperphagia, obesity and hypogonodotropic hypogonadism, is caused by loss 
of expression of paternally inherited imprinted genes on chromosome 15q11-
q13 (Goldstone and Beales 2008). Cornelia de Lange syndrome (CdLS; OMIM 
122470, 300590, and 610759) typically displays growth failure, mental retarda-
tion, typical craniofacial features, bushy eyebrows, hirsutism, hypoplastic ex-
ternal genitalia, hypospadia and undescended testes. Mutations in the NIPBL 
gene have been found to underlie the condition (Krantz et al 2004). Seckels 
syndrome (OMIM 210600) manifests with growth retardation, mental defi-
ciency, microcephaly, central nervous system abnormalities, clinodactyly of the 
fifth-finger and joint dislocations. These patients display a disproportionally 
prominent nose in relation to the face. The affected gene loci in Seckels syn-
drome are 3q22.1-q24 (Goodship et al 2000) and 18p11.31-q11.2 (Børglum et 
al 2001). William’s syndrome (OMIM 194050) is characterized by growth failure, 
mental and developmental retardation, hypercalcemia, cardiovascular anoma-
lies and typical facial features. William’s syndrome is caused by a deletion in 
chromosome 7q11.23 (Morris and Mervis 2000). 
Noonan syndrome (NS; OMIM 163950) is one of the most common syndromes 
transmitted by a Mendelian model. The incidence of affected individuals is 
estimated to be between 1:1000 and 1:2500. NS is a clinically heterogeneous 
disorder predominantly characterized by short stature, dysmorphic facial fea-
tures, neck abnormalities, congenital heart disease and occasionally mild men-
tal retardation (Allanson 2007). The head size in relation to height is mostly 
normal (Sharland et al 1992, Allanson 2007). Germline mutations affecting 
the RAS-MAPK (mitogen-activated protein kinase) pathway have been shown 
to be involved in the pathogenesis of Noonan Syndrome (Kratz et al 2007) 
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as well as in four other rare syndromes with similar clinical features; Leopard 
syndrome, cardio-facio-cutaneous syndrome (CFC; OMIM 115150), Costello 
syndrome (OMIM 218040) and neurofibromatosis type 1 (NF1; OMIM 162200) 
(Schubbert et al 2007). Patients with the 3-M syndrome (OMIM 273750) also 
have normal head circumference in combination with facial dysmorphism and 
short stature. Other features are midface hypoplasia, low set rotated ears, slen-
der long bones, tall vertebral bodies, normal intelligence and a tendency to 
intracerebral and vascular aneurysms (Miller et al 1975, Huber et al 2005). 
                                                                                         Karlberg N  















Pre- and postnatal growth 
failure, normal head cir-
cumference and normal 
intelligence 
Scaphocephaly, occipitofrontal 
bossing, triangular face, low nasal 
bridge and telecanthus, low-set 
rotated ears, small triangular tongue, 
J-shaped sella turcica 
Short stature, general gracility, slender 
long bones, accentuated lumbar lordo-
sis, fibrous dysplasia of long bone, 
high pitched voice, pericardial constric-
tion, hepatomegaly, naevi flammei, 







Pre- and postnatal growth 
failure, normal head cir-
cumference and normal  
intelligence 
 
Facial triangularity, frontal bossing, 
micrognatia with down-curved mouth 
corners and dental crowding, low-set 
rotated ears 
Short stature, extreme constitutional 
gracility, asymmetry of limbs and body, 
clinodactyly of 5
th
 finger, syndactyly of 






Pre- and postnatal growth 
failure, normal head cir-
cumference and intelligence 
Gloomy face, frontal bossing, mid-
face hypoplasia, low-set rotated ears 
Short stature, constitutional gracility, 
slender long bones, tall vertebral 







Pre- and postnatal growth 
failure, mostly normal head 
circumference and mild 
mental retardation 
Epicanthal folds, hypertelorism, low 
nasal bridge, down-slanting palpe-
brae, increased mouth width, retrog-
nathia 
Short stature, short neck with low 
nuchal hair line, spine deformity, 
pectus excavatum, cardiac anomaly, 
micropenis, cryptorchidism, coagu-






Severe pre- and postnatal 
growth failure, microcephaly 
and mental retardation 
Brachycephaly, low nasal bridge, 
bushy eyebrows, long and curly 
eyelashes, long philtrum and thin 
upper lip, micrognathia with down-
curved mouth corners and high 
arched palate 
Very small stature, clinodactyly of 5
th
 
finger, syndactyly of 2-3 toes, simian 
crease, proximal implantation of 
thumb, hirsutism, low nuchal hair line,  
testicular hypoplasia, hypospadia, 






Normal birth length with 
postnatal growth failure, 
microcephaly and mild 
mental retardation 
Almond-shaped face, up-slanting 
palpebrae, narrow bifrontal diameter, 
thin upper lip 
Short stature, obesity,  small hands 
and feet, fair hair and skin with ten-
dency for pickles, micropenis, cryptor-
chidism, hypoplastic labiae and clitoris, 







Pre- and postnatal growth 
failure, mild microcephaly 
and mild mental retardation 
 
Epicanthal folds, medial eyebrow 
flarem, blue eyes, low nasal bridge, 
long philtrum, prominent lips 
Short stature, hypoplastic nails, hallux 
valgus, lordosis, spine deformity, 






Pre- and postnatal growth 
failure, mild microcephaly 
and mild mental retardation 
Dolicocephaly, malar hypoplasia,  
prominent ears, facial telangiectasic 
erythema excerbated by sunlight 
 
Short stature,  syndactyly and clino-
dactyly of 5
th
 finger, hypo- and hyper-
pigmentation of skin, high pitched 
voice, propensity to develop malignan-






Severe pre- and postnatal 
growth failure, microcephaly 
and mental retardation 
 
Receding forehead, prominent nose, 
large eyes, down-slanting palpebral 
fissures, low-set ears, micrognathia 
Very small stature, clinodactyly of 5
th
 
finger, dislocation of hips, slender long 





Pre- and postnatal growth 
failure, microcephaly and 
mental retardation 
Small faces, low nasal bridge and 
telecanthus, epicanthal folds, small 
eyes, short palpebral fissures, broad 
nasal tip, micrognathia, prominent 
dysplastic ears, facial eczema 





finger, syndactyly of 2-3 toes, high 
pitched cry,  propensity to develop 
malignancies, cryptorchidism and 
hypospadia, cardiac defects, iris hypo-




Adapted from Lyons Jones K (Ed.), SmithÕs Recognizable Patterns of Human Malformation, 5
th
 edition 1997. 
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SRS is a well known dysmorphic growth disorder, where subjects are born 
SGA after severe intrauterine growth restriction. The growth failure typical-
ly progresses postnatally and affected individuals are proportionately short 
throughout life. SRS subjects have mostly normal intelligence and their head 
circumference is close to normal standards. Patients display facial triangular-
ity with a tiny jaw and a mouth that tends to curve down, lean constitutional 
appearance, skeletal asymmetry and fifth-finger clinodactyly (Silver et al 1953, 
Russell 1954). The average adult height of males is 151 cm and that of females 
is 140 cm. Many patients have feeding difficulties and hypoglycemia as infants 
(Hitchins et al 2001). SRS is a genetically heterogeneous condition and repre-
sents a phenotype rather than a specific disorder. The diagnosis is therefore 
primarily based upon identification of consistent clinical features, especially 
prenatal and postnatal growth retardation with a close to normal head cir-
cumference. Most SRS cases are sporadic, but some familial cases have been re-
ported (Duncan et al 1990, Ounap et al 2004). Further, molecular studies have 
shown that 5-15% of SRS patients have maternal uniparental disomy (UPD) of 
chromosome 7 (Hannula et al 2001) and approximately 60% show hypometh-
ylation of the H19 ICR (Bruce et al 2009).
3.5.1 Mulibrey nanism
Mulibrey nanism (MUL) is a rare autosomal recessive disorder with severe growth 
failure of prenatal onset and characteristic dysmorphic features, first described 
from Finland in the early 1970s by Perheentupa and co-workers (Perheentupa 
et al 1970, 1973). By today, some 130 patients from different ethnic groups 
have been diagnosed with MUL worldwide (Thorén 1973, Cumming et al 1976, 
Voorhess 1976, Similä 1980, Finni and Herva 1981, Sánchez-Corona et al 1983, 
Cotton et al 1988, Haraldsson et al 1993, Lapunzina et al 1995, Seemanová and 
Bartsch 1999, Avela et al 2000, Jagiello et al 2003, Hämäläinen et al 2004, 2006, 
Doğanc et al 2007), a majority of them from Finland (92). Mulibrey nanism is 
a well-suited prototype of a disease belonging to the Finnish disease heritage 
(Figure 6). It is clearly more common in Finland than elsewhere, with an inci-
dence of approximately 1:40 000 (Lipsanen-Nyman 1986). Most of the Finnish 
patients origin from clustered regions in Savo and North Carelia (Lipsanen-
Nyman 1986). One mutation (Fin-major) is found in nearly all of the Finnish 
patients (Avela et al 2000). 
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Figure 5. A picture of the first diagnosed Finnish 
MUL patient. He was referred to University of 
Helsinki Children’s Hospital at the age of 5.0 years 
with the diagnosis dystrofia gravis. In 1962 his 
case was published by Pitkänen and Perheentupa 
as a glycogen storage disease. The diagnosis was 
later changed to MUL, when patients with simi-
lar problems and dysmorphic features were ob-
served among growth restricted children. 
Figure 6. Pedigree of 18 MUL patients dating back to the shores of Lake Pielinen in North 
Carelia in the early 1600s, displaying a typical founder effect. (Avela and Lipsanen-Nyman, 
unpublished data)
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The originally described patients displayed hypoplastic facial features with 
a prominent forehead and a J-shaped sella turcica (Perheentupa et al 1970, 
1973). The tongue was small and their voice high pitched. Dental crowding was 
also commonly seen (Myllärniemi et al 1978). The patients also displayed typical 
yellowish dots in the midperipheral area of the retina and hypopigmentation 
and pigment dispersion with clusters of pigment in the ocular fundi (Figure 
7) (Raitta et al 1974, Tarkkanen et al 1982). Furthermore, fibrous dysplasia of 
long bones, cutaneous naevi flammei and liver enlargement were encountered 
(Figure 7) (Perheentupa et al 1973). The most striking feature was the heart 
manifestation and patients were frequently compromised by constrictive peri-
carditis and congestive heart failure (CHF) (Tuuteri et al 1974). Hypoglycemia 
was observed in young children in the original cohort. However, no evaluation 
concerning the glucose metabolism has been conducted previously.
The long time course of the Mulibrey heart disease including the results of 
pericardiectomy was described in 2003 by Lipsanen-Nyman and colleagues. 
Constrictive pericarditis, myocardial hypertrophy and fibrosis constituted the 
main elements of the heart disease and more than half of the patients ultimate-
ly developed CHF. A considerable death rate, due to CHF, in early childhood was 
followed by no mortality between 10 and 20 years of age. Thereafter, cardiac 
deaths from CHF due to the heart disease again started to occur. The degree 
of myocardial involvement is the major determinant of prognosis (Figure 8) 
(Lipsanen-Nyman et al 2003). 
Wilms´ tumour has been reported in one Finnish MUL patient (Similä 1980) and 
in two cases outside of Finland (Seemanová and Bartsch 1999, Hämäläinen et al 
2006). The natural growth in MUL has been analyzed in a Finnish monography 
(Lipsanen-Nyman 1986). The results of GH treatment have not been evaluated 
before.
Figure 7. Typical clinical characteristics of MUL illustrated. A. General constitutional 
gracility. The boy has been pericardiectomized and has a feeding tube due to se-
vere feeding difficulties. B. Cutaneous naevi flammei. C. Yellowish dots in ocular 
fundi. D. Deformed lower limb due to fibrous dysplasia of long bones. E. Typical 
craniofacial dysmorphism with frontal bossing, high hair-line, low nasal bridge 
and low-set ears.
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Figure 8. Kaplan-Mayer graphs for the cardiovascular survival free of pericardiec-
tomy in MUL. Although the average survival is shortened (mean 52 years), a nor-
mal life span is not excluded: two elderly ladies with MUL are doing quite well at 
the age of 60 and 77 years. Adapted from Lipsanen-Nyman et al 2003.
3.5.2 TRIM37 mutations underlie MUL
A positional cloning strategy was initiated in the early 1990s to identify the 
pleiotropic gene underlying MUL. In year 2000 four disease-associated muta-
tions (two Finnish, one American and one Czech) were successfully identified 
(Avela K et al 1997, 2000) in a candidate gene corresponding to a previously 
uncharacterized 4111 base-pair (bp) KIAA0898 cDNA clone (Nagase et al 1998), 
coding for a novel 964-amino acid 130kD protein, a member of the RING-B-
Box-Coiled-coil (RBCC) protein family. The identified gene (KIAA0898) located 
on chromosome 17q22-23 was named MUL, referring to Mulibrey nanism, but 
shortly renamed TRIM37 as the causative protein TRIM37 was included in the 
newly characterized TRIM protein family (Raymond et al 2001).
Today, fifteen disease-associated mutations in the TRIM37 gene have been pub-
lished (Table 3) (Avela et al 2000, Jagiello P et al 2003, Hämäläinen et al 2004, 
2006, Kallijärvi et al 2005, Doganc et al 2007). The most dominant mutation 
found (Fin-major) is present in 96% of all Finnish patients (Table 4) (Avela et al 
2000). The Fin-major mutation is a c.493-2A>G transition in the 3´splice site of 
exon 7 resulting in an aberrant splicing at the next AG site which occurs after 3 
base pairs producing a 5-bp deletion at c.493-497. The Finnish minor mutation 
(Fin-minor, c.2212delG), is a 1-bp deletion of a G at nucleotide c.2212 (Avela 
et al 2000). The Fin-minor mutation has only been detected in two Finnish 
patients, who both are compound heterozygotes for this and the Fin-major 
mutation (Avela et al 2000). 
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Figure 9. A schematic structure of the TRIM37 protein. Altogether 19 mutations underly-
ing MUL are known. Fifteen of them produce premature termination codons (PTC) and are 
likely to trigger nonsense mediated mRNA decay. Of the mutations in red, three are missense 
mutations; L76P, G322V, C109S and one a 17 amino-acid deletion of the TRAF domain; E271_
S287del. All 19 TRIM37 mutations identified to this date seem to produce loss of function 
alleles and no genotype-phenotype correlation has been seen in MUL patients (Hämäläinen 
et al 2004, 2006). The Fin-major (R166fs) and Fin-minor (E738fs) mutations are visible in the 
red boxes above.
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(Table 3) (Avela et al 2000, Jagiello P et al 2003, HŠmŠlŠinen et al 2004, 2006, KallijŠrvi 
et al 2005, Doganc et al 2007). The most dominant mutation found (Fin-major) is present 
in 98% of all Finnish patients (Avela et al 2000). The Fin-major mutation is a c.493-2A>G 
transition in the 3«splice site of exon 7 resulting in an aberrant splicing at the next AG site 
which occurs after 3 base pairs producing a 5-bp deletion at c.493-497. The Finnish mi-
nor mutation (Fin-minor, c.2212delG), is a 1-bp deletion of a G at nucleotide c.2212 (Av-
ela et al 2000). The Fin-minor mutation has only been detected in two Finnish patients, 
who both are compound heterozygotes for this and the Fin-major mutation (Avela et al 
2000).  
 
Table 4. Disease associated mutations in Mulibrey nanism 
________________________________________________________________________________________________ 
Mutation Predicted protein consequence Origin of patient Reference 
________________________________________________________________________________________________ 
c.1346dupA p.Ser450fs American Avela et al 2000 
c.326C>G p.Cys109Ser Australian HŠmŠlŠinen et al 2006 
c.860G>A p.Glu271_Ser287del Australian HŠmŠlŠinen et al 2006 
c745C>T p.Gln249X Canadian HŠmŠlŠinen et al 2004 
c.965G>T p.Gly322Val Canadian HŠmŠlŠinen et al 2004 
c.1037_1040dupAGAT p.Met347fs Canadian HŠmŠlŠinen et al 2004 
c.1411C>T p.Arg471X Canadian, Tunisian HŠmŠlŠinen et al 2004 
c.838_842delACTTT p.Thr280fs Czech Avela et al 2000 
c.493-2A>G p.Arg166fs Finnish; Fin-major  Avela et al 2000 
c.2212delG p.Glu738fs Finnish; Fin-minor  Avela et al 2000 
c.227T>C p.Leu76Pro Finnish KallijŠrvi et al 2005 
c.1166A>G p.Tyr389X Finnish * unpublished data 
c.81delG p.Cys28fs French * unpublished data 
c.1233delA p.Lys411fs German * unpublished data 
c.1313+507_1668-207del p.Arg439fs Italian HŠmŠlŠinen et al 2004 
c.2056C>T p.Arg686X Saudi-Arabian HŠmŠlŠinen et al 2004 
1910_1911dupTA p.Gln638fs Swiss * unpublished data 
c.810-1G>A p.Glu271fs Turkish Jagiello et al 2003 
c.1894_1885delGA p.Glu632fs Turkish Doganc et al 2007 
________________________________________________________________________________________________ 
* HŠmŠlŠinen et al unpublished data. 
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3.6 TRIM protein family
More than 60 TRIM proteins are known to this date (Ozato et al 2008). The 
TRIM domain is located in the N-terminus, while various other domains may 
be present in the C-terminus of the protein. The RING domain is defined by 
ordered arrangement of cystein (C) and histidine (H) residues that bind two 
zinc atoms (Freemont et al 1993). The TRIM, RING and B-Box domains are, for 
example, needed for protein-protein interactions and for promoting forma-
tion of larger protein complexes. (Raymond et al 2001). 
The RING domain is thought to be the crucial site for some TRIM proteins in 
mediating their effects on signalling pathways (Ozato et al 2008). RING fin-
gers can act solely or as a multi-subunit RING E3-ligase (Pickart 2001a, 2001b) 
and have been shown to mediate the transfer of ubiquitin from the ubiquitin 
conjugating enzyme to its substrate and act as an ubiquitin E3-ligase (Joazeiro 
and Weissman 2000). The RING domains of many TRIM family members, in-
cluding TRIM5, TRIM8, TRIM11, TRIM22, TRIM25, and TRIM37, have now been 
shown to confer E3-ubiquitin ligase activity, that allows them to mediate ubiq-
uitin events (Toniato et al 2002, Kallijärvi et al 2005, Diaz-Griffero et al 2006, 
Ishikawa et al 2006, Sabile et al 2006, Gack et al 2007, Barr et al 2008, yamauchi 
et al 2008). Recent studies have shown that many members of the TRIM protein 
family are involved in a broad range of biological processes, including innate 
immunity and some that underlie genetic disorders, neurological diseases and 
cancers (Table 4) (Raymond et al 2001, Meroni and Diez-Roux 2005, Ozato et 
al 2008).
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The defective protein in MUL, TRIM37, possesses a typical N-terminus tripartite motif 
(TRIM) comprising a RING domain, a single B-Box domain, and a Coiled-coil region 
(Figure 9) (Borden 1998, 2000, Raymond A et al 2001). The TRIM unit is followed by a 
Tumour necrosis factor (TNF)-Receptor-Associated Factor TRAF domain (Zapata et al 
2001). TRAF proteins are in general involved in TNF receptor signalling, they serve as 
adaptor proteins for a wide variety of cell surface receptors or act as ubiquitin E3-ligases 
regulating a wide range of important cellular functions (Paul 2008). The C-terminus half 
of TRIM37 has no known functional domains (Avela et al 2000). 
 
Table 5. TRIM protein family in human disease 
__________________________________________________________________________________ 
Protein Disease    Ubiquitin E3-ligase 
__________________________________________________________________________________ 
  TRIM1   X-linked FG syndrome - 
  TRIM5   HIV yes 
  TRIM8   Unknown yes 
  TRIM11   AlzheimerÕs disease-like neuronal insults yes 
  TRIM18   X-linked Opitz syndrome - 
  TRIM19   Promelocytic leukemia - 
  TRIM20   Familial Mediterranean Fever - 
  TRIM21   SLE* and Sjšgren syndrome yes 
  TRIM22   Unknown yes 
  TRIM24   Murine leucemia - 
  TRIM25   Antiviral innate immunity yes 
  TRIM27   Thyroid carcinoma - 
  TRIM32   Limb-girdle dystrophy - 
  TRIM33   Thyroid carcinoma - 
  TRIM37   Mulibrey nanism yes 
  TRIM68   SLE* and Sjšgren syndrome - 
__________________________________________________________________________________ 
  Monogenic disorder, * SLE; systemic lupus erythematosus.  Adapted from Raymond et al 2001, Ozato 
et al 2008 
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3.6.1 TRIM37
The defective protein in MUL, TRIM37, possesses a typical N-terminus tripartite 
motif (TRIM) comprising a RING domain, a single B-Box domain, and a Coiled-
coil region (Figure 9) (Borden 1998, 2000, Raymond et al 2001). The TRIM unit 
is followed by a Tumour necrosis factor (TNF)-Receptor-Associated Factor TRAF 
domain (Zapata et al 2001). TRAF proteins are in general involved in TNF recep-
tor signalling, they serve as adaptor proteins for a wide variety of cell surface 
receptors or act as ubiquitin E3-ligases regulating a wide range of important 
cellular functions (Paul 2008). The C-terminus half of TRIM37 has no known 
functional domains (Avela et al 2000).
TRIM37 localizes in immunofluorescence studies to peroxisomes in cell cultures. 
However, no known peroxisomal targeting signals have been shown in TRIM37 
and the localization can be dependent on interaction partners (Kallijärvi et al 
2002). Peroxisomes are small single membrane-bound organelles that partici-
pate in a variety of metabolic functions in the eukaryote cell. The peroxisomes 
play a central role in lipid metabolism and hydrogen peroxide detoxification. 
However, they are also needed for normal intracellular signalling and in regu-
lating normal development (Titorenko and Rachubinski 2004). Defective as-
sembly of peroxisomes results in metabolic or developmental disorders or are 
lethal (Wanders et al 2004). 
Peroxisomal disorders are divided into two categories; peroxisomal enzyme 
deficiencies and disorders of the peroxisomal biogenesis (PBD). PBDs result 
from mutations in the PEX genes, encoding for peroxins that are required for 
appropriate assembly of peroxisomes (Wanders 2004). Typical clinical features 
of PBDs include dysmorphic craniofacial features, neurological disabilities and 
skeletal, hepatological and ocular abnormalities (Wanders 2004). One of the 
most severe phenotypes of PBDs is seen in Zellweger syndrome (ZS; OMIM 
214100), in which patients have multiple congenital anomalies and rarely sur-
vive the first year of life (Brosius and Gärtner 2002). Refsum’s disease (OMIM 
266510, hereditary motor sensory neuropathy type IV, heredopathia atactica 
polyneuritiformis) is an autosomal recessive disorder including features like 
retinitis pigmentosa, blindness, anosmia, deafness, sensory neuropathy and 
ataxia. Patients also display cardiomyopathy and cardiac arrhythmias as a con-
sequence of phytanic acid tissue accumulation (Leys et al 1998).
Single peroxisomal enzyme deficiencies generally result in a much milder phe-
notype than seen in the PBDs. The most common is the X-linked adrenoleukod-
ystrophy (X-ALD; OMIM 300100) caused by impaired peroxisomal oxidation of 
very-long-chain fatty acids (VLCFA) and subsequent accumulation of VLCFA in 
peripheral tissues. The clinical phenotype can vary from manifestations occur-
ring only in the adrenal cortex or the Leydig cells of the testes to more severe 
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symptoms arising from the central nervous system (CNS) (Gärtner et al 1998, 
Moser et al 2000).
MUL shares some features with known peroxisomal disorders, particularly with 
the PBDs. These include growth restriction, facial dysmorphism, retinal pig-
mentary changes, muscular hypotonicity, hepatomegaly and in Refsum´s dis-
ease cardiomyopathy (Leys et al 1989, Sacksteder et al 2000). However, peroxi-
somal disorders, particularly PBDs typically display mental retardation and neu-
rological abnormalities, which MUL-patients mostly lack. Due to overlapping 
clinical findings in MUL and PBD the peroxisomal function has previously been 
assessed in a small cohort of MUL-patients (Schutgens et al 1994). The plasma 
concentrations of phytanic acid, pristanic acid, tri- and dihydroxycholestanic 
acid, and cerotic acid, however, were found to be normal in MUL. Also, the 
profile of very-long-chain fatty acids and de novo plasmalogen biosynthesis 
in fibroblasts were within normal limits. Although no biochemical evidence of 
gross peroxisomal dysfunction has been found (Schutgens et al 1994), MUL has 
since 2002 been regarded as a peroxisomal disorder (Kallijärvi et al 2002). 
3.7 Ubiquitin proteasome system
The exact biological function of TRIM37 is unknown. It is expressed in several tis-
sues during different stages of development in mice (Lehesjoki 2002, Kallijärvi 
2006) and has been shown to possess TRIM-domain dependent ubiquitin E3-
ligase activity (Kallijärvi et al 2005). Ubiquitination is a post-translational modi-
fication of proteins in the eukaryotic cell discovered in the 1980s by Hershko 
and colleagues (Hershko 1983, Hershko and Ciechanover 1998). The process of 
ubiquitination is highly conserved and the ubiquitin-proteasome system (UPS) 
plays a pivotal role in upholding protein homeostasis in the cell by regulat-
ing many central cellular functions, including cell proliferation, adaptation to 
stress, cell death and apoptosis (Hershko and Ciechanover 1998, Pickart 2001a, 
2001b). UPS eliminates misfolded, unassembled, oxidized or otherwise dam-
aged proteins that could form potentially toxic aggregates in the cell. These 
abnormal proteins are rapidly removed from the endoplasmic reticulum, trans-
ported to the cytosol and targeted for destruction by the UPS (Mukhopadhyay 
and Riezman 2007, Paul et al 2008). 
Ubiquitination is an ATP-dependent covalent attachment of an ubiquitin mol-
ecule to its target protein via a cascade of three separate biochemical reactions 
(Figure 10). The ubiquitin process is then usually repeated resulting in a polyubiq-
uitin chain (Pickart 2001a). Substrates marked with a Lys48-linked polyubiquitin 
chain are then targeted to the 26S proteasome in the cell for destruction (Hicke 
and Dunn 2003, Mukhopadhyay and Riezman 2007). On the other hand, monou-
biquitination or Lys63-linked polyubiquitin chains mainly regulate cellular func-
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tions, such as, endocytosis, transcription and most importantly also DNA repair 
(Weissman 2001, Hicke and Dunn 2003, Mukhopadhyay and Riezman 2007). 
    
E3 ubiquitin-ligases can be divided into three groups: 1) E3s containing a HECT-
domain (homologous to E6-AP carboxy terminus) (HECT), 2) E3s containing a 
RING finger and 3) E3s containing a U-Box or a PHD (Plant Homeo-Domain). 
The RING finger ubiquitin ligases constitute the largest subgroup of E3s. The 
ubiquitin E3-ligases regulate the final and most crucial step in the ubiquiti-
nation process and act as specific substrate-recognition elements or “quality 
controllers” of the UPS. The specificity of the ubiquitin-mediated regulation is 
conferred by the low number of E3-ligases, probably about 1000 in the human 
genome. Each of them acts alone with a single or a few E2s to recognize spe-
cific amino acid sequences (Borden 2000, Pickart 2001a, 2001b). 
Figure 10. In step one, the ubiquitin-activating enzymes (E1) form a bond between the ubiq-
uitin molecule and a cysteine residue on the activated site of the enzyme. In step two, the 
activated ubiquitin is transferred and bound to the ubiquitin-conjugating enzyme (E2). In 
step three, the ubiquitin E3-ligase recognizes the specific E2. In step four, E3 tags the target 
protein with ubiquitin. Then, in step five, the ubiquitin process is usually repeated resulting 
in a polyubiquitin chain. Finally in step six, the polyubiquitined protein is targeted to the 26S 
proteasome for proteolysis. Adapted from Hershko and Ciechanover 1998.
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3.7.1 Disorders of UPS
UPS controls the degradation of numerous proteins and regulates signalling 
pathways either by activating or inhibiting them. Dysfunction of UPS could alter 
normal cellular homeostasis and cause a wide range of pathologies in different 
organ systems. In fact, UPS dysfunction has been associated with diabetes mel-
litus, obesity, growth failure and a wide range of cardiac diseases (hypertrophy 
and failure, myocardial ischemia, atherosclerosis and cardiomyopathy) (Wang 
et al 2008). Also genetic or acquired syndromes (i.e. cystic fibrosis, Sjögren syn-
drome), metabolic disorders (Fanconi anemia and α1-antitrypsin deficiency) 
and neurodegenerative disorders (i.e. Alzheimer’s disease, Parkinson’s disease, 
Huntington disease, prion-like lethal disorders and amyotrophic lateral sclero-
sis) (Hegde et al 2007) have been linked to UPS. Also, several cancers (i.e. colon, 
breast, ovarian, renal, Kaposi’s sarcoma and multiple myeloma) have recently 
been connected to UPS (Chen et al 2002, Corn 2007, Bénichou et al 2003), most 
likely by affecting the stabilization of oncoproteins or destabilization of tu-
mour suppressor genes (Sun 2006, Paul 2008).
Defects in all three ubiquitin ligase groups have been associated with human 
diseases (Jiang and Beaudet 2004). Mutations in the UBE3A gene, encoding for 
a HECT family ubiquitin ligase UBE3A, have been found to result in Angelmans’ 
syndrome with severe motor and mental retardation (Kishino et al 1997). 
Liddle syndrome, a hereditary form of early onset hypertension, is caused by 
mutations in the epithelial Na+ channel (ENaC). The mutated region serves as a 
binding site for a HECT family E3-ligase. As a consequence, the endocytosis is 
impaired which leads to an increased Na+ and fluid reabsorption in the distal 
nephron, resulting in elevated blood volume and high blood pressure (Rotin 
2008).
APECED (autoimmune polyendocrinopathy-candidasis-ectodermal dystro-
phy), a disorder of the Finnish disease heritage, has been found to be caused 
by a defective protein AIRE, which is a PHD type zinc finger ubiquitin ligase 
(Nagamine et al 1997). In APECED the main findings are recurrent candidal 
infections, chronic ectodermal alternations and several endocrinological dys-
functions (most importantly hypoparathyroidism and adrenocortical insuf-
ficiency) appearing in childhood and after that during subsequent decades 
(Perheentupa 2002).
Recent evidence links intrauterine growth restriction with impaired ubiquitin 
E3-ligase activity (Provot and Shipani 2007, Sarikas et al 2008). Dysregulation of 
Cullin7 (CUL7), a protein which under normal circumstances assembles a RING 
finger ubiquitin E3-ligase, has been shown to result in the autosomal recessive 
3-M syndrome, characterized by low birth weight, profound pre- and postnatal 
growth retardation, facial dysmorphism and radiological abnormalities (Miller 
et al 1975, Huber et al 2005). In addition, CUL7 -/- mice often die immediately 
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after birth due to respiratory distress, and show progressive growth retarda-
tion already during embryonic period. The mice further present abnormal vas-
cular morphogenesis which is seen also in the placenta. Dermal and hypoder-
mal hemorrhage is detected in mutant embryos, suggesting disturbed vascular 
morphogenesis as one of the underlying causes for the growth problem in 3-M 
syndrome (Arai et al 2003). Recent identification of insulin receptor substrate-1 
(IRS1), a critical mediator of insulin and insulin-like growth factor-1 signalling, 
as the proteolytic target of the CUL7 E3-ligase, provide a molecular link be-
tween CUL7 and a well-established growth and metabolic regulatory pathway 
in humans (Xu et al 2008). CUL7 has also been demonstrated to interact with 
the p53 tumour suppressor protein, further associating CUL7 and RING finger 
E3-ligases to the control of tissue growth (Sarikas et al 2008).
Tumours have strongly been associated with the ubiquitin pathway. The proto-
typic example of this is the tumour suppressor protein p53, which plays an es-
sential role in the cell cycle control, DNA repair, and apoptosis, and may enhance 
cancer through its inadequate actions. P53 is regulated by E3-ligases, mainly by 
the RING-type Mdm2. In the vast majority of cancers Mdm2 regulates p53 both 
by inhibiting its transcription and by increasing its turnover by targeting p53 for 
ubiquitination and proteosomal degradation (Sun 2006, Paul 2008). 
A number of functions have been ascribed to the tumour suppressor protein 
BRCA1, including transcriptional regulation, DNA repair, and induction of ap-
optosis. BRCA1 possesses N-terminal RING finger and has been shown to be 
an E3-ligase (Fang et al 2002). Tumour-associated mutations in the RING fin-
ger have been shown to abolish its E3 activity. Indeed, inactivating mutations 
of BRCA1 have frequently been reported in breast cancer (Hashizume et al 
2001) and in ovarian carcinoma (Paul 2008). Also, down-regulation of tumour-
suppressing sub-chromosomal transferable fragment cDNA (TSSC5) has been 
observed in certain tumours, particularly Wilms’ tumour. TSSC5 encodes for a 
transporter-like RING-finger protein, RING105, acting as an ubiqutin E3-ligase 
(Sun 2006, Scott et al 2008).
The von Hippel-Lindau tumour-suppressor gene (VHL) is inactivated in the von 
Hippel-Lindau disease (VHL; OMIM 193300), which is an autosomal dominant 
cancer syndrome that results from germline mutations in the VHL gene on 
chromosome 3p25-26 (Sun 2006, Jung et al 2006). VHL is also inactivated in 
sporadic cases of clear-cell renal cell carcinoma (Paul 2008, Shehata et al 2008). 
The VHL protein (pVHL) functions as part of an ubiquitin E3-ligase complex 
that targets proteins for 26S proteasomal degradation. Its best-characterized 
substrate is the hypoxia-inducible factor-alpha (HIF-α). Loss of pVHL and subse-
quent up-regulation of HIF target genes has been shown to cause tumours of 
highly vascular nature (Jung et al 2006). Additional functions of pVHL may also 
be important in preventing the development of clear-cell renal cell carcinoma 
by maintaining the stabilization of p53 (Paul 2008).
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4. AIMS OF THE STUDy
The aims of this study were to analyze the clinical and histopathological char-
acteristics of MUL in the national cohort of Finnish patients. MUL is a dysmor-
phic growth disorder caused by recessive mutations in the TRIM37 gene on 
chromosome 17q22-23. The specific aims were:
1. To characterize the clinical features of MUL from infancy to the time of diag-
nosis, and to propose new clinical diagnostic criteria for MUL. 
2. To analyze and describe the key elements of the glucose and lipid metabo-
lism in subjects with MUL.
3. To evaluate and describe the natural growth pattern of MUL patients and to 
analyze the outcome of long-term GH treatment.
4. To study the specific histopathological and immunohistochemical character-
istics of MUL in different organ systems.
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5. PATIENTS AND METHODS
Since the early 1970s, the clinical care of the Finnish MUL patients has mostly 
been centred to the University of Helsinki Children’s Hospital. This has gener-
ated a large amount of clinical unpublished data. A significant part of this 
retrospective data together with the new data from a clinical follow-up study 
initiated in year 2000 make up the material of this thesis. 
5.1 Subjects
The series included all known 92 Finnish MUL patients diagnosed before 2007, 
88 of them homozygous for the Fin-major mutation (c.493–2A>G) of the 
TRIM37 gene (Avela et al 2000). Four patients were compound heterozygotes; 
two for the Fin-major and Fin-minor (c.2212delG) mutations (Avela et al 2000), 
and the remaining two patients had a c.227T>C/Fin-major (Kallijärvi et al 2005) 
and c.1166A>G/Fin-major (Hämäläinen et al unpublished data) genotype, re-
spectively. The diagnosis has been genetically confirmed directly in all but five 
of the patients. In four of them, DNA was obtained from family member(s); 
one parent couple, two single parents, and one sibling, all carriers of the Fin-
major mutation (c.493–2A>G). The phenotype of the remaining patient left 
no doubt about the diagnosis. In seven of the families, there was an affected 
sibling. In five of these siblings, the clinical findings were constant, but in two 
families the phenotype showed minor variation. 
5.2 Clinical data collection
The hospital records of 89 patients (49 females) were retrospectively analyzed 
(I, II, IV). Data on clinical events, appearance and dysmorphic features were re-
corded and the patients were photographed. Obstetric and growth data were 
collected from local hospitals, child welfare centres and schools. The patients’ 
parents, relatives, and physicians were interviewed for missing details.
All patients underwent a physical examination at 6-12 month intervals during 
childhood and puberty with assessment of height, weight, and pubertal stage 
according to the criteria of Tanner (Tanner and Whitehouse 1979). Height and 
weight measurements were made by the clinician or a trained nurse. Standing 
heights were measured with a stadiometer to the nearest millimetre and the 
mean of three measurements was used. The weight was measured with an or-
dinary scale to the nearest 100 g. The blood pressure was measured three times 
while the subjects were seated, and the last two measurements were averaged 
for analysis. GH treated patients were reviewed at baseline and at 3, 6, 9 and 
12 months after commencement and subsequently every 6 months.
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Growth data from birth to final height on 72 (40 females) patients were col-
lected (I, III). A standard arginine- or insulin-arginine tolerance test was used to 
evaluate the GH secretion. A peak serum GH response >10 μg/l was considered 
normal and a value between 5 and 10 μg/l indicated partial GH deficiency. 
The patient was considered GH deficient if the peak serum level was <5 μg/l 
in two separate tests. Thirty of the patients (18 females) were treated with re-
combinant human GH since early 1990´s for a median period of 5.7 years. The 
efficiency of GH treatment was analyzed based on data from these patients, 
while the natural growth was evaluated from the untreated patients and data 
on the treated patients prior to commencement of GH therapy (III). 
Finnish growth standards were used for height and weight analysis (Sorva et 
al 1984). Height standard deviation score (hSDS) was calculated for calendar 
age. Final hSDS was calculated from the standards of the Finns at the age of 18 
years (I, III). The weight of the patients was defined as the percent deviation 
from the age- and sex-specific median weight-for-height (WFH) (Pere 2000) (I, 
II, III). Adult weights were expressed also as body mass index (BMI) (II, III). The 
birth length and weight of patients born preterm (before 38 weeks of gesta-
tion) were extrapolated to term by using Finnish standards of prenatal growth 
(Pihkala et al 1989) (I, III). The onset of puberty was defined as stage P2G2 in 
boys and a stable breast stage of M2 in girls (Tanner and Whitehouse 1979) 
(II). 
Also radiological [x-rays, ultrasonography (US), computer tomography (CT), and 
magnetic resonance imaging (MRI)] (I, II, III, IV), and histological data (biopsy 
and autopsy samples) (III, IV), and data on the clinically followed patients were 
retrospectively analyzed. Fifteen patients in the survey were evaluated only 
from hospital and autopsy records and samples obtained at autopsy (I, II, III, IV). 
Two of the patients died during follow-up and an autopsy was performed. 
5.3 Laboratory examinations
Blood glucose (venous whole-blood glucose), glycohemoglobin A1C and serum 
insulin were measured after an overnight fast with concomitant measurement 
of serum leptin and plasma uric acid, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma glutamyl transferase and triglycerides as well 
as plasma total cholesterol, high-desity lipoprotein (HDL), and low-density lipo-
protein (LDL) (I, II, III). In patients receiving GH serum IGF-1 was measured every 
6 months. Blood counts, blood glucose and serum concentrations for thyroid 
and liver function were followed as safety parameters annually (III). 
Serum IGF-1 levels were measured by radioimmunoassay (RIA) (Incstar, Stillwater, 
Minnesota USA) and serum leptin levels were assessed by specific RIA (Linco 
Research Inc, St. Louis, Missouri USA) (II, III). GH concentrations were measured 
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by monoclonal immunoradiometric assay (Gif-sur-yvette, Cedex, France) prior 
to the year 1995 and thereafter by AutoDelfia time-resolved immunofluromet-
ric assay (PerkinElmer, Wallac, Turku, Finland). 
A comprehensive evaluation of the glucose and lipid metabolism was per-
formed in 65 (37 females) patients (II). An oral glucose tolerance test (OGTT; 
glucose load 1.75g/kg, maximum 75 g) with concomitant measurements of 
blood glucose and serum insulin was used to classify the subjects as having nor-
mal glucose tolerance, impaired glucose tolerance (IGT; the 2-h venous whole 
blood glucose value from 6.7-9.9 mmol/l), or type 2 diabetes (fasting venous 
whole blood glucose ≥6.1 mmol/l or the 2-h value ≥10.0 mmol/l) on the basis of 
WHO criteria (Alberti and Zimmet 1998). The degree of insulin sensitivity was 
determined from the ratio of fasting glucose and insulin levels (Vuguin P et 
al 2002) and the whole-body insulin sensitivity index was calculated from the 
OGTT values according to Stumvoll (Stumvoll et al 2000, 2001). Metabolic syn-
drome was determined according to the NCEP Adult Treatment Panel III (ATP III 
2001, Fedder et al 2002) and hypertension as blood pressure >95th percentile 
for age and sex.
5.4 Radiology
A radiological survey with X-rays of the skull, thorax, and long bones was con-
ducted (I, III, IV). US of the abdomen (children and adults) (II, IV) and thyroid 
gland (adults) (IV) were performed and in cases of tumour suspicion, MRI was 
arranged without delay (IV). The bone age (BA) was determined from an x-ray 
of the palm and wrist according to the method of Greulich and Pyle (Greulich 
1950, Greulich and Pyle 1950) (III).
5.5 Histology and immunohistochemistry 
The tissue specimens were obtained on clinical grounds at surgery or as percuta-
neous core needle biopsy samples or at autopsies of 17 MUL patients. Formalin-
fixed paraffin-embedded samples were used for the histological and immuno-
histochemical studies. Immunoperoxidase staining was performed in a tradi-
tional way, using sections of formalin-fixed, paraffin-embedded tissue samples. 
Microwave treatment in 10 mM/l citric acid for 10 min was performed, or Dako 
Target Retrieval Solution (S1699) (DakoCytomation, Glostrup, Denmark) was 
used to improve the antibody penetration. The slides were then incubated with 
antibodies against endothelial cell markers CD34 (Dako-Cytomation, Glostrup, 
Denmark) and CD31 (PECAM-1; Dako), α-smooth muscle actin (α-SMA; Dako), 
perivascular epithelioid cell (PEC) marker HMB-45 (Dako) and cellular prolifera-
tion marker MIB-1 (KI-67; Dako). Amplification of the primary antibody reac-
tion was achieved by incubating the sections with biotinylated secondary an-
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tibody (Vector Elite ABC Kit; Vector Laboratories Inc., Burlingame, CA, USA) or 
TSA Indirect (Pyramide Signal Amplification Kit, Perkin-Elmer LAS Inc., NEL700). 
Histological specimens were reviewed by the experienced pathologist Dr. Riitta 
Karikoski.
5.6 Statistics 
Clinical, laboratory and metabolic parameters were correlated with age, weight 
for height (II, III), and with the hSDS increment during the preceding year (III). 
The explanation rate was expressed as an R2-value. The Wilcoxon test was used 
to compare parameters between the GH treated and untreated patient groups. 
P-value less than 0.05 were defined as statistically significant. 
5.7 Ethics
The study was approved by the Institutional Ethical Review Board at the 
University of Helsinki. The use of clinical and autopsy material for research 
purposes was approved by the National Authority for Medico-Legal Affairs in 
Finland (TEO). Patients and/or their guardians gave informed consent. Also, 





The clinical and histopathological characteristics of MUL were analyzed in the 
national cohort of Finnish patients mostly homozygous for the Fin-major muta-
tion in the TRIM37 gene. The results indicate that MUL forms a distinct clinical 
entity, although organ manifestations vary considerably from early childhood 
to adulthood. The most consistent findings in our cohort were the characteris-
tic dysmorphic features, pre- and postnatal progressive growth failure, severe 
insulin resistance with tendency to abbreviations in glucose and lipid metabo-
lism with increasing age, and high frequency of malignant tumours and benign 
adenomatous and vascular lesions, as well as disturbed organogenesis.
6.1 Clinical characteristics of MUL
Clinical features were evaluated in 85 (46 females) subjects with MUL. Most of 
the pregnancies preceded without major problems. Nineteen of the pregnan-
cies (23%) had been monitored due to poor fetal growth. Other complications 
included pre-eclampsia (three cases), anti-Rhesus immunization (a pair of sib-
lings), gestational diabetes (one), and varicella zoster infection (one). Fifteen 
mothers (18%) had experienced miscarriages priorly. Length of gestation var-
ied from 32 to 42 weeks (median 39 weeks); 90% of the children were born at 
full term. Labour was normal in all but three cases, in which an urgent cesarean 
section was performed because of threatening asphyxia. Cardiac involvement 
was evident in only one newborn with Wolf-Parkinson-White syndrome (WPW) 
causing paroxysmal supraventricular tachycardial attacks already in utero 
(Tikanoja and Taipale 2004). Fourteen babies needed supplementary oxygen 
after birth. Respiratory distress syndrome was diagnosed in three; two of them 
were born prematurely. Apgar score at 5 minutes was on average 8 (range 
2-10).
After a relatively normal newborn period half of the infants failed to thrive. 
Feeding difficulties and upper respiratory infections, including frequent pneu-
monias were the most common clinical problems (Table 5). Episodes of res-
piratory failure induced by an infection occurred in 25% and nine of the 85 
infants had to be resuscitated (Table 6). Four and nine patients had congestive 
heart failure by the age of 1.0 and 2.0 years, respectively; four of them died. 
Psychomotor development was normal or slightly delayed in a great major-
ity of the infants. Mild hypotonicity was evident in nearly half of the infants, 
and some delay in both motor development and speech was noted in nearly 
one third. Age at the first steps and the first words ranged from 0.8-2.6 years 
(mean 1.2 years) and 0.9-3.1 years (mean 1.3 years), respectively. A mildly hy-
drocephalic skull with frontal bossing and abnormally wide fontanelles evoked 
suspicion of hydrocephalus in 15% of the infants (Table 6).
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The diagnosis was commonly 
made in early childhood (me-
dian age 2.1; range 0.02 to 52 
years), so that one third were 
younger than 1 year and two 
thirds were younger than 5 
years. At the time of diagnosis, 
the characteristic craniofacial 
features combined with poor 
growth were the dominant 
characteristics in the great 
majority (Table 7, Figure 11), 
and in all but four of the pa-
tients (95%) the hSDS was be-
low -2.5. Also, characteristic 
radiological findings including 
slender long bones with thick 
cortex and narrow medullary 
channel and a low and shallow 
(J-shaped) sella turcica were 
present in nearly all patients 
(Table 7, Figure 11). Fifteen pa-
tients (18%) had signs of heart 
disease; ten of them had con-
gestive heart failure (Table 6), 
and four had pericardial con-
striction necessitating pericar-
diectomy. Thirty-eight patients 
(45%) had hepatomegaly and 
six of them tumour-like lesions in the liver. Wilms’ tumour was detected in two 
patients before MUL was diagnosed. Both had non-symptomatic hematuria 
with a palpable abdominal mass as the only signs. 
Gross organ anomalies of the heart and urogenital system were also observed 
(Table 7). A peculiar high pitch and slight coarseness of the voice was noted 
in nearly all of the prepubertal patients. Characteristic ocular findings were 
yellow dots in the midperiphery of ocular fundi, seen in 80% of the patients. 
Additional ocular findings were retinal hypopigmentation and pigment disper-
sion with clusters of pigment in the retina. Two thirds of the patients had cu-
taneous naevi flammei and 15% had fibrous dysplasia, most commonly in the 
lower limbs (Figure 11). A slight asymmetry of the extremities was noted in 17 
patients (20%), which in two thirds was due to shortening by fibrous dysplasia. 
At diagnosis, the only abnormal laboratory parameters were the elevated se-
rum levels of the aminotransferases seen in nearly half of the patients; AST up 
to 110 U/l (mean 61 U/l) and ALT up to 193 U/l (mean 41 U/l). 
                                                                                         Karlberg N  





The clinical and histopathological characteristics of MUL were analyzed in the national 
cohort of Finnish patients mostly homozygous for the Fin-major mutation in the TRIM37 
gene. The results indicate that MUL forms a distinct clinical entity, although organ mani-
festations vary considerably from early childhood to adulthood. The most consistent find-
ings in our cohort were the characteristic dysmorphic features, pre- and postnatal pro-
gressive growth failure, severe insulin resistance with tendency to abbreviations in glu-
cose and lipid metabolism with increasing 
age, and high frequency of malignant tu-
mours and benign adenomatous and vas-
cular lesions, as well as disturbed organo-
genesis. 
 
6.1 Clinical characteristics of MUL 
 
Clinical features were evaluated in 85 (46 
females) subjects with MUL. Most of the 
pregnancies preceded without major prob-
lems. Nineteen of the pregnancies (23%) 
had been monitored due to poor fetal 
growth. Other complications included pre-
eclampsia (three cases), anti-Rhesus im-
munization (a pair of siblings), gestational 
diabetes (one), and varicella zoster infec-
 
Table 6. Problems in infancy in 85 patients with MUL 
______________________________________________ 
 
Feature                                        Frequency (% ) 
______________________________________________ 
 
Neonatal problems  
  Respiratory problems                   31 
     Ventilatory assistance needed                    20 
     Cyanosis while crying                    15   
  Feeding difficulties                    30 
     Nasogastric feeding tube needed                   17 
  Suspicion of hydrocephalus                     6 
  Suspicion of sepsis                     6 
  Cardiac arrhythmia                    1 
Growth failure                     96 
Infections 
   Upper respiratory infections >4/year                 51 
   Pneumonia                     47 
   Necessitating hospital care                    30 
   Three or more pneumonias                   27 
   Ventilatory assistance needed                    25 
   Intubation needed                   14 
   Middle ear infections >4/year                    38 
Feeding difficulties                   50 
   Vomiting                     39 
   Difficulties in sucking                    31 
   Nasogastric feeding tube needed                    31 
   Delay in switching to solid foods                    24 
   Fatigue during eating                   21 
   Percutaneous gastrostomy needed                  6 
Muscular hypotonicity                  46 
Suspicion of hydrocephalus                  16 
Hypoglycemia                    15 
Congestive heart failure                   11 
Resuscitation during first year of life                   11 
   Due to infection                     9 
   Due to aspiration                   1 
   Due to arrhythmia                   1 
Death during infancy                    5 
   Due to infection                  2.5 
   Due to congestive heart failure                 2.5 
______________________________________________ 




        
 
Table 7. Clinical features at the time of diagnosis in 85 MUL patients  
______________________________________________________________ 
 
Feature                                          Frequency (% ) 
______________________________________________________________ 
Head 
  Characteristic face: triangular face, high and broad 
  forehead; low nasal bridge and telecanthus                   90 
  Scaphocepaly with occiptofrontal bossing                    90 
  Low and shallow (J-shaped) sella turcica                    89 
  Laterally rotated orbital fossae                     80 
  Hypoplastic tongue                     80 
  Small hypoplastic face                     71 
  Orbital hypertelorism                    64 
  Low set located posteriorly rotated ears                    54 
  Dental crowding                      50 
  High hairline                      45 
  Wide fontanelles and sutures in infancy                                         37  
  Abnormally wide metopic suture                     31 
  Cleft palate                      2 
Body 
  Thin extremities                     99 
  Accentuated lumbar lordosis                     96 
  General gracility                     95 
  Narrow shoulders                    94 
  Small bell shaped thoracic cage                    94 
  Barrell-like trunk                     92 
  Cutaneus naevi flammei                     65 
  Hypoplastic buttocks                     52 
Constitution 
  Slender long bones                    93 
  Relative proximal shortness of limbs                   90 
  Large head relative to stature                     90 
  Large hands and feet relative to stature                   67 
  Fibrous dysplasia of long bone                     15 
  Skeletal asymmetry                     15 
Heart 
  Signs of heart disease                     18 
  Cardiomegaly                     14 
  Dyspnoea                     12 
  Prominent veins on upper body                    11 
  Cardiac anomaly                     15 
  ASD                       8 
  VSD                       5 
  Open ductus arteriosus                      3 
  Congestive heart failure                    12 
  Pericardial constriction                      6 
Liver 
  Hepatomegaly                      45 
  Ascites                                                                                    11 
  Liver tumour-like lesions                     9 
Urogenital 
  Renal anomaly                                                                                 8 
  Hydronephrosis                                                                                6 
  Abnormally located kidney                       5 
  Hypoplastic kidneys                      5 
  Horseshoe kidney                     12 
  Male genital anomaly*                      6 
     Cryptorchidism                      6 
  Female genital anomaly                      2 
     Hyperplastic labiae                       1 
     Prominent clitoris                      2 
  WilmsÕ tumour                       3   
Nervous system 
  Yellowish dots in the ocular fundi                       79 
  Muscular hypotonicity                     68 
  Large cerebral ventricles and basal cisternae                    44 
  Slow speech development                     30 
  Slow motor development                     29 
Skin 
  Cutaneous naevi flammei                    65 
______________________________________________________________ 




Figure 11. Typical craniofacial, radiological and constitutional features of MUL. The 
face is triangular and the skull scaphocephalic with a J-shaped sella turcica (arrow). 
The orbital fossae are slightly upward-slanting (arrow) and fibrous dysplasia of 
the slender long bones was frequently seen (arrows). The heart appears large in 
relation to the small and bell-shaped thoracic cage. The ribs are also thin (arrow). 
Patients display general gracility and hands and feet apperar large in relation to 
the height. Figures partly adapted from the Journal of Medical Genetics 2004 (I).
6.2 Natural growth in MUL
Growth data were analyzed in 72 (40 females) MUL patients. At birth, MUL 
infants were both short and light and 95% were born SGA. The median birth 
length and weight adjusted to 40 weeks of gestation were 44.8 cm (median 
hSDS -3.0) and 2300 g (median SDS -3.0) for the girls and 45.0 cm (median hSDS 
-2.8) and 2350 g (median SDS -2.9) for the boys, respectively. The median SDS 
for OFC was -0.5 (range -0.9-0.8) indicating spared cranial growth with macro-
cephaly relative to birth length. The growth failure progressed in early infancy 
with a median hSDS decrement of 1.1 from birth to 2.0 years of age (Figure 12). 
Growth in children with severe feeding difficulties (five children; median hSDS 
-5.1, range -3.8 to -5.9) and congestive heart failure (nine children; median 
hSDS -5.4, range -4.3 to -7.4) was more compromised than in subjects without 
these problems (median hSDS -4.4). Two children (3%) were born severely pre-
mature at gestation week 32, with a birth length SDS of -6.4 and -4.0, respec-
tively. Their postnatal growth was most severely affected so that their hSDS at 
2.0 years of age was -7.8 and -7.3, respectively.
RESULTS
48
Figure 12. Ninety-five percent of MUL babies were born SGA and their growth 
failure progressed postnatally. Figure with permission from the Journal of Medical 
Genetics 2004 (I).
Catch-up in growth with a gain in hSDS of more than 1.0 occurred only in 
five (6%) of the infants. At the age of 2.0 years, the hSDS was on average -4.4 
(range 0.1 to -7.8) (Figure 12). WFH decelerated continuously during the two 
first years (Table 8, Figure 14). Infant growth deceleration was followed by a 
spontaneous but incomplete catch-up growth, which lasted up to school age 
(Figure 14). The children remained slim until puberty (Table 5, Figure 14). MUL 
subjects showed a wide individual variation in the onset of puberty with a 
median age of 12.5 and 13.0.years for boys and girls, respectively (Table 5). The 
puberty was spontaneous but the development of the secondary sexual char-
acteristics was slow and incomplete in both sexes. At the onset of puberty the 
median hSDS was -3.6 (range -6.3 to -1.0, Table 8, Figure 15). Postpubertally, 
WFH started to increase particularly in the females (Table 8, Figure 14, 15). The 
final adult height averaged 136 cm (range 130-155 cm; median hSDS -5.1) in 
females and 150 cm (range 147 to 162 cm; median hSDS -4.1) in males.
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Figure 13. GH treatment improved growth temporarily so that the growth velocity reached 
its peak 12 to 18 months after the start. The long-term effect however remained modest. A 
median gain of 5 cm in height was achieved. Figure with permission from Pediatrics 2007 
(III). 
6.3 Growth hormone treatment in MUL
GH production was assessed in 38 MUL children at a median age of 5.1 years 
(2.0-15 years). The serum peak GH level averaged 8.2 μg/l (range 1.3-23.2). The 
response was interpreted as normal in 26%, subnormal in 58%, and low in 
16%. The distribution was similar in those individuals who were started on GH 
treatment (normal 27%, subnormal 62%, low 11%). Serum IGF-1 levels were 
normal, but half of the prepubertal children had an IGF-1 value in the lowest 
quartile of the normal range.
Thirty (18 females) patients were treated with GH for a median period of 5.7 
(range 1.8-13.4) years (Figure 13). At commencement (median age 4.4) their 
median hSDS was -4.7 (range -7.8 to -2.0). During the first year the hSDS incre-
ment was on average 1.0 SDS, and by the onset of puberty it was 1.8 (range 
0.2-2.7). Also, WFH increased after commencement of GH therapy (Table 5). At 
the onset of puberty the median height was 0.7 SD greater in the GH treated 
patients (p<0.01, Table 8, Figure 14). Bone maturation accelerated after 8.0 
RESULTS
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years of age in the GH treated patients, so that a significant difference (1.09 
vs. 0.92) in the BA/CA ratio was evident at the age of 10.0 years (p<0.01) com-
pared to the untreated subjects. The difference remained significant through-
out puberty so that at the age of 14 years this ratio was 1.05 and 0.95 in the 
treated and untreated patients, respectively (p<0.03) (Figure 14). Also the du-
ration from stage 2 breast development to menarche was significantly shorter 
and menarche occurred nearly 3.0 years earlier in the GH treated as compared 
to untreated girls (Table 8). Sixteen patients (8 females) receiving GH have 
reached their final height with a median of 142 cm (range 137-154 cm, me-
dian hSDS -4.2) and 155 cm (range 150-163 cm; median hSDS -3.6) in females 
and males, respectively (Figure 13, 14, Table 8). The GH treated females and 
males reached their final height 1.1 and 0.6 years earlier than their untreated 
counterparts (p<0.002 and p<0.02, respectively). At final height, the difference 
in hSDS between the treated and untreated patients was 0.6 (approximately 
5 cm) (Table 8, Figure 13, 14). Females seemed to benefit slightly more (by 0.4 
SDS) than the males (p<0.05). 
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ence (1.09 vs. 0.92) in the BA/CA ratio was evident at the age of 10.0 years (p<0.01) 
compared to the untreated subjects. The difference remained significant throughout pu-
berty so that at the age of 14 years this ratio w s 1.05 and 0.95 in the treated and un-
treated patients, respectively (p<0.03) (Figure 14). Also the duration from stage 2 breast 
development to menarche was significantly shorter and menarche occurred nearly 3.0 
years earlier in the GH tr ated as com ared to untreated girls (T ble 8). Sixteen patients 
(8 females) receiving GH have reached their final height with a median of 142 cm (range 
137-154 cm, median hSDS -4.2) and 155 cm (range 150-163 cm; median hSDS -3.6) in 
females and males, respectively (Figure 13, 14, Table 8). The GH treated females and 
males reached their final height 1.1 and 0.6 years earlier than their untreated counter-
parts (p<0.002 and p<0.02, respectively). At final height, the difference in hSDS between 
the treated and untreated patients was 0.6 (approximately 5 cm) (Table 8, Figure 13, 14). 
Fe ales seemed to benefit slightly more (by 0.4 SDS) than the males (p<0.05).  
 
 
Table 8. Growth from early infancy to final height in MUL. 
__________________________________________________________________________________________________ 
 
                                                                                          Natural growth                                GH-treatment 
__________________________________________________________________________________________________ 
 
Stage of growth                            Unit        Median      Range       Number      Median      Range       Number      p-Value 
__________________________________________________________________________________________________ 
Early infancy 
   Birth length                                  SDS          -3.3        -1- -5.4            43             -3.6         -1.5- -6.4          29            NS 
   Birth weight                           SDS          -2.7      -1.8- -3.6           43             -3.0         -1.4- -4.0          29            NS 
Infancy 
   Height at 2.0 years                      SDS          -4.4       -0.7- -6.2          41             -4.7         -1.3- -7.8          29             NS 
   Weight-for-height at 2.0 years       %             -22         -2- -28            32             -22             2- -35             27            NS 
Childhood 
   Height at 5.0 years                      SDS          -3.8       -2.0- -6.9          26             -4.2          -2.0- -6.5          27            NS 
   Weight-for-height at 5.0 years       %             -20         -2- -32            26             -23             -2- -32            27            NS 
   Height at 8.0 years                      SDS          -3.5       -0.3- -6.5          23             -3.5          -1.5- -5.9          24            NS 
   Weight-for-height at 8.0 years       %             -17         16- -27           23              -17             15- -29          24            NS   
Puberty 
   Pubertal stage P2G2/M2             years          12.5        9.2-15           26             11.6            8.8-15           15            NS 
   Menarche                                    years            15        10.5-17          13               12             10-15.5           8            0.05 
   Height at P2G2/M2                      SDS           -3.6      -6.3- -1.4         22              -2.9          -4.2--0.9          12            0.01 
   Weight-for-height at P2G2/M2       %              -14         27-22            22              -14             21--24           12           NS 
   Height in mid-puberty                  SDS            -3.5      -5.8- -1.3         19             -2.9           -5.3--1.8          14           0.02 
   Weight-for-height in mid-puberty   %               -4          -21-58           19              -8               -21-20           14           0.02 
Adulthood 
   Final height                             SDS           -4.6      -6.7- -2.2         26            -4.0            -4.9- -2.1         14           0.05 
   Weight-for-height at final height     %               20         -2-75             26               3              -22-34            14           0.002 
__________________________________________________________________________________________________ 





Figure 14. Median hSDS from birth to final height (A). GH therapy had only mi-
nor impact on final height (hSDS +0.6). Progression of bone age (BA) in relation 
to chronological age (CA) in GH-treated and untreated subjects (B). GH therapy 
accelerated bone maturation after 8 years. Median weight-for-height (WFH) for 
females (C) and males (D). At adult height, subjects treated with GH were slimmer 
in both genders. Figure with permission from Pediatrics 2007 (III).
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6.4 Glucose and lipid metabolism in MUL
Glucose metabolism and lipid metabolism were studied in 65 MUL patients 
aged 1.1-55 years (Table 9). A dramatic change in the glucose metabolism was 
observed with increasing age. While children (<10 years) had low fasting in-
sulin and frequently (50%) showed hypoglycemic values (blood glucose <3.4 
mmol/l),  90% of adults showed high fasting and post-load peak insulin values 
ranging up to 1450 mU/l (median 430 mU/l). Serum basal and post load insu-
lin levels correlated well with the C-peptide levels, and the explanation rate 
(R2- value) was 0.6121 and 0.657, respectively. The fasting glucose and insulin 
ratio and Stumvoll indexes showed a 10- and 4-fold decrease with advancing 
age, indicating the development of severe insulin resistance. Half of the adults 
(aged >20 years) had type 2 diabetes and an additional 42% showed IGT. The 
median ages revealing IGT and type 2 diabetes were 18.3 (range 3.1- 42.3) and 
26.0 (9.5-55.2) years, respectively. 
GH treatment did not significantly worsen the pre-existing insulin resistance. 
Contrary, at final height, the subjects treated with GH remained significantly 
slimmer than the untreated patients (p<0.002) (Figure 14). Serum leptin, uric 
acid, total cholesterol, and triglycerides also increased with age (Table 9). 
Hypertension (>95th percentile) was observed in 81%, and 70% of the adults 
fulfilled the criteria for metabolic syndrome according to the NCEP Adult 
Treatment Panel III (NCEP 2001, Fedder et al 2002). As adults, the frequency of 
metabolic syndrome was twice as high (64% vs. 33%) in the untreated (N=11; 
median age 23.9 years) compared to the GH treated subjects (N=12; median 
age 24.2 years). 
Figure 15. The development of in-
sulin resistance was accompanied 
by changes in body composition 
and lipid metabolism. While prepu-
bertal children were thin, clinically 
evident abdominal obesity started 
to develop after puberty. Of adults 
42% were overweight (WFH >20%). 
Note the same female subject at 
6.0 years and 20 years of age. The 
transformation from a thin child to 
a mildly overweight adult is evi-













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.5 Organogenesis and tumours in MUL
Findings in various organs were evaluated by radiology [US and MRI] in 76 pa-
tients, aged 0.7 to 77 years, and from autopsy samples in 17 deceased patients. 
Overall, 232 tumorous lesions were encountered (Table 10). Also, ectopic tissues 
and abnormal organ development were evident in the histological samples.
6.5.1 Histological findings
Disturbed organ development was seen in several internal organs. The general 
architecture of the adrenal gland was clearly disturbed. Cortical and medullar 
structures intermingled and the adrenal parenchyma commonly penetrated 
through the capsule into the surrounding fat or renal tissue (Figure 16). Also, 
fetal-type cortical architecture was present in several specimens. One female 
patient was found to have a focus of ovarian tissue in her kidney. The pan-
creatic gland was atypically folded in all histological specimens, with lipid de-
posits within and around the gland. The spleen was congestive in all patients 
examined post mortem. It contained lymphocytes but the white pulpa lacked 
lymph follicles. Similarly, a severe lymphatic depletion in the lymph nodes was 
evident.
A high frequency of benign tumours was noted in different organ systems. The 
majority of the lesions were cystic and benign adenomatous lesions. In radiol-
ogy or histology 52% of MUL subjects had renal cortical cysts, 26% had pancre-
atic cysts, 20% had thyroid cysts, 15% had cysts in the central nervous system 
and 11% had cysts in the reproductive organs. Bilateral nodular cortical hyper-
plasia of the adrenal gland was present in 87% of the histological samples ana-
lyzed (13/15) and all histological samples of the pancreas (13/13) revealed hy-
perplastic islets, as in focal endocrine hyperplasia. Twenty-two (25%) patients 
had fibrous dysplasia of long bones, four had nodular thyroid goitre, two had 
renal angiomyoliopmas, one had a renal hamartoma containing ovarian tissue, 
one had a pancreatic serous cystadenoma and one infant had a small medullar 
pheochromocytoma. Moreover, six adrenal cortical adenomas and two thyroid 
adenomas were encountered (Table 8). More than half of the postpubertal 
females (12/22) had benign ovarian fibrothecomas (Karlberg et al 2004). 
Fifteen malignant tumours were encountered in thirteen patients (15%), seven 
of them occurred in the kidney. Wilms’ tumour was diagnosed in five (6%) pa-
tients (mean age, 2.5 years; Table 10). Two patients were diagnosed with renal 
papillary carcinoma and two with a thyroid papillary carcinoma. A medullar 
thyroid carcinoma combined with squamous-cell metaplasia was also encoun-
tered. Other malignancies were two gynecological cancers (ovarian carcinoma 
and endometrial adenocarcinoma), one gastrointestinal carcinoid tumour, one 




Figure 16. The renal and adrenal tissues mixed frequently, and in one case the ad-
renal gland (large arrow) was totally surrounded by renal tissue (small arrow).
6.5.2 Liver peliosis
The most consistent tumour lesion was found in the liver. The lesions (5-60 mm) 
were noted in almost half (35) of the 72 MUL patients studied by US (Table 10, 
Figure 17 A). Most lesions resembled hemangiomas, but a minority had a more 
cystic appearance. The lesions usually enlarged with time, but in approximately 
one-third of the patients the lesions fluctuated in size during the follow-up. 
Ten of the lesions clearly shrank and temporarily disappeared in five patients. 
Intense homogeneous tumour-suspect lesions were detected in 20 of the 22 
patients studied by MRI (Figure 17 B). Some of the larger lesions appeared 
cystic with a more heterogeneous signalling. 
The liver was enlarged and congestive in all 17 patients at autopsy (0.7-48 
years). Sixteen (94%) had multiple macroscopic hemangiomatous lesions (5-
70 mm). Histological specimens from the 17 autopsies and 20 liver biopsies 
(2.4-40 years) revealed marked sinusoidal dilatation (peliosis; Table 10, Figure 
19) and disorganized sinusoidal pattern in relation to central veins and portal 
tracts. The basic lobular arrangement was focally disturbed and the central 
veins in these areas were dilated and had unusually thick walls. The portal 
regions and biliary tracts were mostly normal, but the degree of fibrosis in-
creased with time. Hepatocytes were normal or enlarged, containing variable 
amounts of micro- and macrovesicular lipid droplets (20-90%). Fatty liver was 




Figure 17. Tumour suspect lesion of the liver seen in US (A) and in MRI (B). The le-
sions consist of disorganized sinusoidal architecture and increased dilatation and 
rupture of the liver sinusoids (liver peliosis). 
Figure 18. Macroscopic section of a liver taken at autopsy of a twelve year old boy. The liver 
appears nodular and the colour is heterogenous. The peliotic areas are more intensely red in 
colour (arrows).  
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Figure 19. A. Strong sinusoidal dilatation and rich vascularity of a peliotic liver lesion. B. 
Strong staining with vascular endothelial marker CD34 in the peliotic liver in comparison 
with healthy controls (C).
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6.5.3 Non-compaction cardiomyopathy 
 
The heart was enlarged in all 17 patients examined post mortem (0.7-48 years). The 
endocardium appeared thick and the pericardium was adherent to the underlying myo-
cardium, but no inflammatory cells were present as reported before (Lipsanen-Nyman M 
et al 2003). The thickness of the myocardium varied and in large areas closely resem-
bled the papillary muscles, with highly trabeculated fibres suggestive of non-compaction 
Table 10. Radiological and histological findings in 89 MUL patients 
_________________________________________________________________________________ 
    
        Radiology         Histology  Age of detection     
        (years.) 

















Liver       
   Peliosis 35/72 20/22 16/17 20/20 14.7 0.8Ð37 
Kidney      0.3-42 
   Cysts 30/72 18/22 16/17 6/6 13.6  
   Renal hamartoma 0/72 0/22 1/17 0/6 40  
   Angiomyolipoma 1/72 1/22 1/17 0/6 40  
   WilmsÕ tumour 3/72 5/22 0/17 5/6 2.5 2.2-3.7 
   Renal papillary carcinoma 0/72 0/22 2/17 1/6 22.3 17-28 
Pancreas       
   Cysts 13/72 11/22 10/11 2/2 17.5 9.8-48 
   Serous cystadenoma 0/72 0/72 0/11 1/2 24  
   Endocrine hyperplasia 0/72 0/22 11/11 2/2 16.7 0.7-41 
Thyroid gland       
   Cysts 12/30 3/3 6/12 3/3 24.5 1.7-42 
   Adenoma 0/30 1/3 0/12 2/3 25.5 14-36 
   Papillary carcinoma 1/30 0/3 1/12 1/3 32.1 28-40 
   Medullary carcinoma 0/30 0/3 0/12 1/1 40  
   Parathyroideal adenoma 0/30 0/3 0/12 1/1 36  
Adrenal gland       
   Nodular cortical hyperplasia 15/72 9/22 11/13 2/2 22.5 1.4-49 
   Adrenocortical adenoma 2/72 3/22 5/13 1/2 32.3 1.4-40 
   Pheocromocytoma 0/72 0/22 1/13 0/2 1.4  
Urogenitalia       
   Ovarian fibrothecoma 12/22 0/0 1/9 12/12 29 16-52 
   Ovarian cysts 1/22 0/0 0/0 0/0 11  
   Ovarian carcinoma 1/22 0/0 0/0 1/12 33  
   Endometrial adenocarcinoma 1/22 0/0 0/0 1/12 45  
   Epididymic cysts in males 6/15 0/0 3/9 0/0 24 2-42 
Central nervous system       
   Cysts 0/0 6/15 7/15 0/1 8.9 0.8-36 
   Neuropituitary histiocytosis 0/0 1/15 0/15 1/1 8.6  
Other       
   Carcinoid tumour 0/1 1/1 0/0 1/1 21  
   Acute lymphoblastic leukemia 0/0 0/0 0/0 1/1 3.6  
   Fibrous dysplasia of long bone 22/89* 0/0 0/0 7/7 7.5 1.3-19 
_________________________________________________________________________________ 





The heart was enlarged in all 17 patients examined post mortem (0.7-48 years). 
The endocardium appeared thick and the pericardium was adherent to the 
underlying myocardium, but no inflammatory cells were present as reported 
before (Lipsanen-Nyman M et al 2003). The thickness of the myocardium var-
ied and in large areas closely resembled the papillary muscles, with highly 
trabeculated fibres suggestive of non-compaction cardiomyopathy (Figure 20). 
The myofibrils were mostly hypertrophic but were in some areas thin and an-
gulated, as in acute ischemia. Histologically, the blood vessels had unusually 
thick walls and were folded, as in other internal organs. Atherogenic vascular 
changes were noted in more than half of the autopsied patients (N=10, median 
age 29 years). Five of them had died of CHF due to severe cardiomyopathy; two 
had died of cancer and three of other causes.
Figure 20. Non-compaction cardiomyopathy seen in histology. The myocardium is 
especially trabeculated and the myocytes abnormally short resulting in cardiac re-




The blood vessels had unusually thick walls and the capillaries and larger ves-
sels were strongly dilated and folded not only in the liver and heart but also 
in the kidneys, lungs, pancreas, brain, adrenal and thyroid gland, as well as in 
the hilar region of the lymph nodes, were the blood vessels were exceptionally 
large and folded (Figure 21). In liver the endothelial cell markers CD31 and es-
pecially CD34 were strongly positive (Figure 19). Also, the staining for the myo-
cyte marker α-SMA was intensely positive (Table 11). These staining patterns 
were clearly different from control livers, where the staining of all markers was 
restricted to portal areas (Figure 19). The liver lesions showed little mitotic ac-
tivity and a weak expression of the proliferation marker MIB-1 (Table 11). Also, 
the marker for PEComa, HMB45, was not expressed in these lesions (Table 11).
In general, there was a strong positive staining for the endothelial cell mark-
ers CD31 and CD34, and for α-SMA in the internal organs (Table 11, Figure 19, 
21), while the staining for MIB-1, p53 and HMB-45 were negative. Blood ves-
sels in the lymph nodes showed very strong staining for CD34. The expression 
of α-SMA was intense around larger vessels, particularly in the hilar region. 
Control sections stained negative.
Figure 21. The staining pattern of lymph nodes. Large, abnormally folded blood 
vessels (arrows) in the hilar region seen in haematoxylin and eosin staining (A). 
The staining was strongly positive with CD34 (B) and α-SMA (D). However, the 
vessels were surprisingly negative for CD31 (C). This combined with the strong 
positivity of CD34 indicates a disturbed angiogenesis. *Lymph node.
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Table 11. Immunohistochemial analysis of paraffin-embedded tissue specimens in MUL 
_____________________________________________________________________________________ 
Organ Nr  CD34 CD31 α-SMA HMB-45 MIB-1 p53 
Liver 5 +++ ++ +++ - - - 
Kidney 5 +++ ++ +++ - - - 
Adrenal gland 4 +++ + ++ - - - 
Thyroid gland 4 ++ + ++ - - - 
Pancreas  4 ++ + ++ - - - 
Lung 4 +++ + ++ - - - 
Lymph node 4 +++ - +++ - - - 
_____________________________________________________________________________________ 




Mulibery nanism (MUL) is an autosomal recessive growth disorder with mul-
tiple organ manifestations and no major neurological handicap enriched in 
the Finnish population. MUL is caused by mutations in the TRIM37 gene on 
chromosome 17q22-23, encoding for TRIM37 with ubiquitin E3-ligase activity. 
The clinical and histopathological characteristics were analyzed in the Finnish 
cohort of MUL patients mostly homozygous for the Fin-major mutation. The 
results show that MUL patients form a distinct clinical and diagnostic entity, 
although clinical features vary from infancy to adulthood. While poor growth, 
feeding difficulties and respiratory infections dominates early life, young adults 
were especially prone to develop metabolic syndrome, as well as benign and 
malignant tumours in several organs.
7.1 Clinical features of MUL
Clinical features of MUL have previously been reported in the original Finnish 
cohort (Perheentupa et al 1970, 1973, Lipsanen-Nyman 1986) and as sporadic 
cases from different populations (Thorén 1973, Cumming et al 1976, Voorhess 
1976, Sánchez-Corona et al 1983, Cotton et al 1988, Haraldsson et al 1993, 
Lapunzina et al 1995, Seemanová and Bartsch 1999, Avela et al 2000, Jagiello 
et al 2003, Hämäläinen et al 2004, 2006, Doğanc et al 2007). These reports 
are partly based on genetically unconfirmed patients. Our present series is the 
largest and most comprehensive describing the key clinical features of MUL 
from infants to adults, as well as at the time of diagnosis. Our results show that 
MUL patients are born SGA and are generally both abnormally short and light 
for length. Moreover, they fail to exhibit early or late catch-up in growth. The 
distinct early growth pattern in MUL resembles the postnatal growth of in-
fants born very preterm at week 23-25th of gestation experiencing extrauter-
ine growth restriction (EUGR) (Gibson et al 2000, 2003, Niklasson et al 2003, 
Finken 2006, Wit et al 2006, Pilling et al 2008). However, the very preterm 
children commonly catch up within 48 months after birth (Gibson et al 2003), 
while MUL infants display a continuous deceleration both in relative height 
and weight through infancy and early childhood. This wasting is followed by a 
spontaneous, but incomplete catch-up in growth until school-age. 
MUL infants, although born at term, display immature features resembling 
those of premature infants, such as the early growth pattern and relative mac-
rocephaly (Gibson 2007, Finken 2006). The craniofacial skeleton displays imma-
turity and the peculiar shape of sella turcica resembles the shape of the bony 
sphenoid before the cartilaginous dorsum sellae has ossified (Myllärniemi et 
al 1978). Also, the scaphocephalic shape of the skull with its wide sutures and 
prominent forehead and the size relationship between the skull and face are 
all supportive of delayed pre- and postnatal maturation in MUL (Myllärniemi 
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et al 1978). These features may also evoke false impression of hydrocephalus. 
Other major problems that MUL subjects share with preterm and SGA children 
are feeding difficulties. In general, swallowing is poorly coordinated in infants 
born prematurely or SGA and the degree of dysfunction is inversely related 
to the degree of immaturity and growth failure (Tuchman 1988, Selley et al 
1990). The oral anatomy of mature infants is particularly well suited for eat-
ing by sucking, with the tongue being relatively large, filling the oral cavity 
(Stevenson and Allaire 1991, Derkay and Schechter 1998, Matsuo and Palmer 
2008). Infants with MUL, however, have a hypoplastic and anteriorly triangular-
shaped tongue. This is evident in nearly 70% of these infants. The craniofacial 
hypoplasia, maturational delay (Myllärniemi et al 1978) and muscular hypoto-
nicity probably all contribute to the feeding difficulty. Early recognition and 
management are important because dysphagia may contribute to the failure 
of catch-up in growth and poses a threat to the child’s nutrition and respiratory 
function (Kelly et al 2007a, 2007b).
Patients with MUL are also prone to respiratory tract infections and have an 
exceptionally high risk for pneumonia. No immunological defects have been 
demonstrated in Finnish MUL patients and the basis of this susceptibility is not 
known. However, in autopsy specimens a severe lymphatic depletion in lymph 
nodes was frequently evident and interestingly, recent studies have shown that 
TRIM proteins are expressed in response to interferons and involved in biologi-
cal control of innate immunity (Raymond et al 2001, Zou and Zhang 2006, Ozato 
et al 2008). For instance, TRIM25, which is an ubiquitin E3-ligase, has been 
shown to be important in antiviral activity (Gack et al 2007). Interestingly, the 
gene encoding for TRIM25 is located close to TRIM37 on chromosome 17q23.2. 
In our patient cohort, two patients who died of an infection early in infancy 
were post-mortem found to have adrenal cortical hypoplasia. In autopsy sam-
ples from deceased MUL-patients, patchy proliferation of myofibroblasts with 
thickening of the alveolar walls and hemosiderine-containing macrophages 
were frequent findings in the lungs, while hypoganglionosis or aganglionosis 
of the enteric plexus were frequently observed in the intestine. The frequent 
pneumonias have been suspected to be a combined consequence of dysphagia 
due to aspiration and a lower respiratory capacity. As infections quite easily 
tend to result in respiratory failure, a suboptimal immune and stress response 
could further complicate the situation. 
7.2 Diagnosis of MUL
The clinical diagnosis of MUL is challenging during the first months of life. 
Infants with intrauterine growth failure constitute a heterogeneous group of 
patients and many of them have chromosome abnormalities, monogenic disor-
ders or familial or sporadic syndromes (Albertsson-Wikland and Karlberg J 1994, 
Albertsson-Wikland et al 1998, Hannula et al 2001, Wit et al 2005). Diagnosis of 
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MUL should be considered in infants born SGA with progressive growth failure 
and poor weight gain, hepatomegaly and characteristic craniofacial features. 
The analysis of the clinical features in this large cohort of Finnish MUL-patients 
led to revised diagnostic criteria. Importantly, while none of the clinical fea-
tures was constant, 99% of our patients presented with at least three of the 
major and one of the minor signs. One patient had only two major signs, but 
he had three of the minor signs (Table 12). 
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Table 12. Diagnostic signs and their prevalence in 85 MUL-patients (46 
females and 39 males). For diagnosis three major signs with one minor 
sign are required or two major signs with three minor signs. 
_______________________________________________________________ 
 
Signs                                                                                       Frequency (% ) 
_______________________________________________________________ 
   
Major signs 
     
   Growth failure (A or B or C) 
       
      A) small for gestational age (SGA), lacking catch up growth        95 
       
      B) height in children 2.5 SDS below population mean for age     94 
      
      C) height in adults 3.0 SDS below population mean                    90 
     
   Characteristic radiological findings (A or B) 
      
      A) slender long bones with thick cortex and                    93 
           
          narrow medullar channels   
      
      B) low and shallow (J-shaped) sella turcica                    89 
     
   Characteristic craniofacial features                     90 
       
      Scaphocephaly, triangular face, high and 
      
      broad forehead, low nasal bridge and telecanthus 
     
   Characteristic ocular findings 
       
      Yellowish dots in retinal mid peripheral region                    79 
    
   Mulibrey nanism in a sibling                     17 
  
Minor signs 
     
    Peculiar high pitched voice                     96 
     
    Hepatomegaly                      70 
    
    Cutaneous naevi flammei                     65 
     
    Fibrous dysplasia of long bone                     25 
_______________________________________________________________ 
Adpted from J Med Genet 2004 (I). 
 
 
Identification of the causative gene, TRIM37, has allowed genetic confirmation of the 
diagnosis. Since the Fin-major accounts for 98% of all Finnish MUL-associated muta-
tions (Avela et al 2000), screening for this mutation seems sufficient enough in Finnish 
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Identification of the causative gene, TRIM37, has allowed genetic confirma-
tion of the diagnosis. Since the Fin-major accounts for 96% of all Finnish MUL-
associated mutations (Table 4) (Avela et al 2000), screening for this mutation 
seems sufficient enough in Finnish families. Genetic confirmation in non-Finn-
ish patients requires sequencing of the whole TRIM37 gene. Molecular genetics 
can also provide MUL diagnosis prenatally. However, since MUL is an extremely 
rare disorder, prenatal diagnosis is rational only in families known to be af-
fected with this disorder.
Altogether 19 mutations underlying MUL are known (Table 4). Fifteen of 
them produce a premature termination codon (PTC) and are likely to trigger 
nonsense mediated mRNA decay; three are missense mutations; Leu76Pro, 
Gly322Val, Cys109Ser and one a 17 amino-acid deletion of the TRAF domain; 
Glu271_Ser287del. All 19 TRIM37 mutations identified to this date seem to pro-
duce loss of function alleles since no genotype-phenotype correlation has been 
seen in MUL patients (Hämäläinen et al 2004).
7.2.1 Differential diagnosis
While prenatal onset growth failure and craniofacial features are important clin-
ical characteristics of MUL, they are not unique and are seen in other dysmorphic 
conditions (Figure 22). For instance, subjects with SRS display a similar growth 
pattern with pre- and postnatal growth restriction, constitutional gracility, nor-
mal head circumference and craniofacial dysmorphism, precisely as MUL patients 
(Silver et al 1953, Russell 1954, Escobar et al 1978, Wollmann et al 1995, Price 
et al 1999, Hannula et al 2001). In early infancy, feeding difficulties and failure 
to thrive are commonly seen in both conditions (Price et al 1999, Hannula et al 
2001, Hitchins et al 2001). The clinical overlapping makes SRS the most important 
differential diagnosis (Table 13, Figure 22). However, both these conditions have 
their own distinct characteristics. Clinodactyly, small face with marked triangu-
larity, micrognathia with down-turned mouth corners, and skeletal asymmetry 
are characteristics of SRS (Price et al 1999, Hannula et al 2001, Hitchins et al 
2001). Hepatomegaly, heart failure due to pericardial constriction or cardiomyo-
pathy, yellow dots in ocular fundi, fibrous dysplasia and cortical thickening of 
long bones are key characteristics of MUL and do not occur in SRS. However, 
SRS is considerably heterogeneous both clinically and genetically (Hannula et al 
2001, Hitchins et al 2001, Gicquel 2005, 2008, Abu-Amero et al 2008, Rossingnol 
et al 2008, Bruce et al 2009). The classical features of SRS (Silver et al 1953, Russell 
1954, Escobar et al 1978, Price et al 1999), those that are shared with MUL, are 
associated with hypomethylation of the H19 ICR locus on chromosome 11p15.5 
(Bruce et al 2009). A milder SRS phenotype exists in patients with maternal uni-
parenteral disomy of chromosome 7 (Hannula et al 2001). Also, three atypically 
mild cases of MUL have been diagnosed in the Finnish patient cohort, all ho-
mozygous for the Fin-major mutation.
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Figure 22. An infant with SRS (A and B) and an infant with MUL (C and D) at an 
age close to 2.0 years. The craniofacial features resemble each other considerably, 
making SRS the most important differential diagnosis of MUL. 
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Table 13. Differences in phenotype between SRS and MUL 
______________________________________________________________________ 
   
 SRS MUL 
Features   
______________________________________________________________________ 
Craniofacial   
   relative macrocephaly 100% 90% 
   facial triangularity 100% 89% 
   bossed forehead 96% 86% 
   micrognathia  100% 20% 
   dental crowding 65% 50% 
   down turned mouth corners 58% - 
   low-set backwards rotated ears 77% 54% 
   J-shaped sella turcica - 89% 
Growth   
   short stature 100% 95% 
   birth length (SDS) -3.7 -3.0 
   birth weight (SDS) -3.1 -2.9 
   2.0 year height (SDS) -4.5 -4.4 
   2.0 year weight-for-height (%) -26 -22 
Musculosceletal   
   clinodactyly of 5th finger 85% - 
   skeletal asymmetry 88% 15% 
   syndactyly of 2-3 toes 50% - 
   mucsle hypotonicity 46% 68% 
   thick cortex of long bone - 93% 
   fibrous dysplasia of bone - 25% 
Heart and liver   
   congestive heart failure - 51% 
   hepatomegaly - 70% 
Metabolics   
   *fasting blood glucose in prepubertal children 4.4 mmol/l 4.2 mmol/l 
Urogenitalia   
   cryptorchidism 62% 6% 
Other features   
   high pitched voice 38% 96% 
   yellowish dots in ocular fundi - 80% 
   cutaneous naevi flammei - 65% 
   feeding difficulties 38% 50% 
   slow speech development 27% 30% 
   slow motor development 27% 29% 
______________________________________________________________________ 
* Fasting blood glucose from 24 prepubertal MUL subjects (median age 9.4 years) and  
  12 prepubertal SRS subjects (median age 9.2 years) (Karlberg et al unpublished 
  data). Other findings in SRS patients constitute the features seen in 26 patients with  




7.3 Long-term GH treatment in MUL 
 
The importance of the GH-IGF-axis is indisputable in postnatal growth (Walenkamp MJ 
and Wit 2006). GH deficiency and resistance have previously been reported in short 
children born SGA (de Waal et al 1994, Boguszewski et al 1995, Saenger et al 2007) as 
well as reduced levels of IGF-1 and IGF-2 (de Waal et al 1994, Murphy et al 2006). Also, 
gene knockout studies have shown a major impact of IGF-1 on pre- and postnatal growth 
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7.3 Long-term GH treatment in MUL
The importance of the GH-IGF-axis is indisputable in postnatal growth 
(Walenkamp MJ and Wit 2006). GH deficiency and resistance have previously 
been reported in short children born SGA (de Waal et al 1994, Boguszewski 
et al 1995, Saenger et al 2007) as well as reduced levels of IGF-1 and IGF-2 (de 
Waal et al 1994, Murphy et al 2006). Also, gene knockout studies have shown 
a major impact of IGF-1 on pre- and postnatal growth (Murphy et al 2006). 
Recent discoveries show variation in methylation patterns regulating imprint-
ing and expression of IGF-2 in SRS (Girquel et al 2008, Bruce et al 2009). The 
role of GH-IGF-axis in the poor growth of MUL-patients is unclear, but some 
patients presented a partial GH deficiency and showed low normal levels of 
serum IGF-1.  
The long term GH treatment had minor impact on the final height of MUL sub-
jects (hSDS increment of 0.6 = 5 cm), which is in line with results reported previ-
ously in some dysmorphic growth disorders and skeletal dysplasias (Azcona et 
al 1998, Cianfarani 1999, Kelnar 2003, Hagenäs et al 2005). The gain in height 
was mainly achieved before the onset of puberty, as has been seen in previ-
ous studies on SGA (Dahlgren et al 2005). A substantial catch-up growth was 
observed especially during the first two years of treatment. At discontinuation 
of the GH therapy (BA 14 years, height velocity <2cm / year), a median hSDS in-
crement of 1.9 compared to baseline data was observed. Bone maturation and 
growth arrest, however, occurred early in patients receiving GH, which explains 
why the final adult height in MUL patients still remained very poor as com-
pared to the general population. Importantly, no adverse effects of long-term 
GH treatment, in regard to heart disease or tumour frequency, have emerged 
in the treated subjects. Nevertheless, the modest impact on the final height 
should be kept in mind when considering the grounds for this treatment. 
Interestingly, the GH1 gene encoding for human GH is located on chromosome 
17q22-24, close to TRIM37 (17q22-23). Mutations in the GH1 have been re-
ported to result in bioinactive GH and short adult stature (Moseley and Phillips 
2000). After secretion, GH is bound to its receptor (de Vos et al 1992), which 
requires an active ubiquitin system to mediate biological actions of GH, such as 
promoting growth through increased expression of IGF-1 in peripheral tissues 
(Strous and van Kerkhof 2002). New evidence links normal UPS function even 
stronger to the regulation of human growth. Recently discovered mutations 
in the gene cullin7 (CUL7) on human chromosome 6p21 have been identified 
to result in the autosomal recessive 3-M syndrome, with features resembling 
those of MUL, including severe pre- and postnatal growth retardation, facial 
dysmorphism, normal head circumference and intelligence (Miller et al 1975, 
Huber et al 2005). Interestingly, the CUL7 protein is crucial in assembling an 
ubiquitin E3-ligase complex and thereby promotes ubiquitination (Huber et al 
2005, Sarikas et al 2008). Mutations in the CUL7 gene strongly link UPS dysfunc-
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tion to the pathogenesis of prenatal-onset growth failure in humans (Huber et 
al 2005, Sarikas et al 2008). MUL seems to be the newest addition to this list. 
 
7.4 Metabolic concerns of MUL
Hypoglycemia is a frequent concern in SGA and preterm babies (Gibson 2007, 
Saenger et al 2007, Miller et al 2008). Brain function is highly dependent on glu-
cose as major fuel. When exposed to hypoglycemia neurophysiologic changes 
occur (Beardsall et al 2007). Stress effector systems like the hypothalamic-pi-
tuitary-adrenal axis (HPAA) are activated to increase peripheral blood glucose 
levels important for survival. Suggestions have been made that pre- and ante-
natal stress could permanently alter the function of developing organ systems 
and result in metabolic concerns, such as insulin resistance, type 2 diabetes 
and cardiovascular disease, later in life (Fall et al 2002, Kajantie et al 2002, 
2006). For instance, insulin resistance has been associated with SGA caused by 
unfavourable mother-child environment followed by early postnatal weight 
gain to obesity (Eriksson et al 2003, Veening et al 2003). In MUL, however, 
the prenatal-onset growth failure is caused by a fetal gene defect and only a 
modest weight gain is observed before puberty. Moreover, the link between 
SGA and insulin resistance is not definitive as prepubertal subjects with SRS, 
who have a phenotype and growth pattern similar to MUL-patients, do not 
show corresponding abnormalities in their glucose metabolism (Karlberg et al 
unpublished data).
In most monogenic diseases leading to type 2 diabetes, the pathogenic process 
can be explained by dysfunction of the pancreatic β-cells or obesity (O’Rahilly et 
al 2005, Farooqi and O’Rahilly 2005, McCarthy and Hattersley 2008). Contrary 
to this, MUL-subjects presented exceptionally high post load serum insulin lev-
els and fatty liver as well as acanthosis nigricans often detectable already in 
slim, prepubertal MUL children. Additionally, the weight gain did not correlate 
with development of insulin resistance. On the other hand, lipodystrophy with 
low leptin secretion (O’Rahilly et al 2005, Herranz et al 2008) was not involved 
in the development of insulin resistance. In MUL, serum leptin levels were un-
expectedly high compared to the weight gain. 
Under normal healthy conditions leptin plays a central part in regulation of 
body weight (Rector et al 2008). High leptin levels are associated with obesity 
and also with accumulation of fat in the liver (Fishman et al 2007). However, 
both lean and obese insulin resistant individuals have been shown to have 
excess fat in their liver. Lipid accumulation can occur either through increased 
uptake or synthesis of fatty acids or as a consequence of reduced or defective 
fatty acid oxidation (Shulman 2000). The reasons why some patients accumu-
late fat in the liver or in other organs are poorly known. Data from human and 
animal studies connect ectopic lipid accumulation in muscle and liver to the 
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development of insulin resistance. In animal models excess fat deposits have 
also been shown to cause organ dysfunction of the heart (Cheng et al 2004, 
Lee et al 2004) and pancreas (McGarry 2002). Ectopic fat deposits, in particular 
liver fat, correlates well with increased levels of serum liver enzymes (S-ALT and 
S-AST) (Bellentani et al 2000, Kotronen et al 2007) and all components of the 
metabolic syndrome (Kotronen et al 2007, Kotronen and yki-Järvinen 2008). 
The accumulated fat possibly interferes with the normal intracellular insulin 
signalling leading to insulin resistance (van Herpen and Schrauwen-Hinderling 
2007). The insulin resistance can initially be overcome by an increased insu-
lin secretion, but when the secretory capacity of the beta-cells decline, type 
2 diabetes develops (Poitout 2004). New evidence strongly suggests that lipid 
accumulation in the pancreatic islets is a central trigger of beta-cell dysfunc-
tion in diabetes (Sharma et al 2004, Maedler et al 2003). This lipotoxity could 
be one explanation why insulin resistant individuals cannot meet the increas-
ing insulin demand and eventually develop type 2 diabetes (McGarry 1992, van 
Herpen and Schrauwen-Hinderling 2007). In MUL the highly elevated serum 
leptin levels together with the early development of fatty liver, suggest that 
accumulation of fat in the liver and also in the pancreas might be the crucial 
step in the development of type 2 diabetes in these subjects. 
TRIM proteins regulate a broad range of biological processes in humans (Ozato 
et al 2008). Some are associated with genetic disorders, neurological diseases 
or even cancer (Meroni and Diez-Roux 2005). Many TRIM proteins have been 
shown to confer ubiquitin E3-ligase activity crucial for mediating their biologi-
cal effects on signalling pathways within the cells (Raymond et al 2001, Ozato 
et al 2008). UPS has been shown to affect the regulation of insulin signalling 
cascades and insulin action (Rome et al 2004). Moreover, UPS is involved in the 
internalization of the insulin receptor, in the control of the amount of insulin 
receptor substrates (IRS1 and IRS2), and in cellular insulin degradation. UPS 
also regulates transcription factors and nuclear receptors mediating insulin-
induced gene expression. For instance, the peroxisome-proliferator-activated-
receptors (PPARs) are involved in the regulation of lipid and glucose metabo-
lism and in the control of inflammatory response (Blanquart et al 2002, Floyd 
and Stephens 2002, Rome et al 2004). Interestingly, inherited variation in the 
PPAR-gamma gene has been implicated in the pathogenesis of type 2 diabe-
tes (Altshuler et al 2000) and also in reduced fetal growth (Jaquet et al 2002). 
Recent reports indicate that altered UPS function might be one of the molecu-
lar mechanisms of insulin resistance in many pathological situations. Insulin 
resistance is suggested to develop from inappropriate degradation of impor-
tant molecules in the insulin signalling pathway, such as IRS1 and IRS2 (Rui et 
al 2002, Wing 2008). In addition, defective insulin secretion has been proposed 
to occur due to UPS-mediated degradation of IRS2 in the β-cells of the pancreas 
(Casas et al 2007). The UPS also appears to be involved in regulating lipid syn-
thesis in adipocytes and lipid production by the liver and could influence the 
development of obesity (Donaldson 1979, Qi et al 2006, Wing 2008). TRIM37 is 
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the first member of the TRIM superfamily to influence the insulin homeostasis. 
The effects of TRIM37 on the insulin signalling cascades are still unknown.
7.4.1 Metabolic aspects of GH therapy
Since GH is an insulin antagonist and may induce hyperinsulinemia, we were 
concerned about the glucose metabolism in the GH treated MUL patients. 
Importantly, the pre-existing insulin responsiveness did not change signifi-
cantly during GH treatment in prepubertal or pubertal children. Moreover, 
the adult patients who had received GH therapy had lower WFH and BMI and 
the deterioration of their glucose metabolism was less severe as compared to 
untreated MUL subjects. Similar favorable changes in body composition, BMI 
and the lipid atherogenic index have been presented in large cohorts of SGA 
children on GH therapy (van Pareren et al 2003, Boonstra et al 2003). Thus, the 
GH therapy appears at least to some extent slow down the development of the 
metabolic syndrome in MUL. 
In MUL children the greatest increment in height was observed in those with 
the highest serum fasting and post load peak insulin concentrations suggesting 
that insulin might improve the spontaneous childhood growth, and accelerate 
the short term catch-up growth after commencement of GH therapy. Indeed, 
insulin is a well known growth promoting factor both pre- and postnatally. It 
regulates the IGF-1 concentration by facilitating the binding of GH to its recep-
tor, stimulates the production of IGF-1, and increases bioavailability of IGF-1 by 
suppressing the hepatic synthesis of IGFBP (Böni-Schnetzler et al 1991, O’Brien 
et al 1991). Moreover, in a recent study involving non-GH treated SGA girls 
a rapid progression in pubertal growth tempo and progression to menarche 
driven by insulin was observed (Ibáñez et al 1998, 2006). Our results are in line 
with this, suggesting that the aggravated levels of insulin might underlie the 
faster pubertal tempo to menarche seen in MUL females on GH. 
7.5 Cardiac problems in MUL
The heart disease comprises of two components; constrictive pericarditis 
(Tuuteri et al 1974) and thickening of the myocardium resulting in cardiac re-
striction (Lipsanen-Nyman et al 2003). The degree of heart involvement domi-
nates the clinical state as well as the prognosis (Lipsanen-Nyman et al 2003). 
However, only 12% of our patients had congestive heart failure at the time of 
diagnosis (median 2.1 years) and half of the adult patients have been reported 
to be free of major heart problems (Lipsanen-Nyman et al 2003). 
In histological analysis we found that the normal development of the heart was 
disturbed, resulting in a focally trabeculated myocardium and non-compaction 
cardiomyopathy (Finsterer et al 2002, Wessels et al 2008). UPS has been shown 
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to be involved in pathophysiological processes in muscle tissues (Fagan et al 
1987). Skeletal muscle degeneration that follows denervation, immobilization 
and catabolic states, such as starving, fasting, and cancer-induced cachexia, has 
been shown to activate the UPS (Sun 2006, Paul 2008). In muscle, specific ubiq-
uitin E3-ligases (muscle-specific RING-finger proteins or MuRFs) exist. MuRFs 
are the key regulatory components of the UPS in heart and skeletal muscle. 
They are responsible for the degradation of skeletal muscle proteins in wast-
ing (Fagan 1987, Fischer et al 2000), and also for maintaining the anabolic 
and catabolic balance in cardiomyocytes (Toth et al 2006, Wang et al 2008). 
Interestingly, the role of UPS appears to be essential for up-holding normal 
cardiac function and muscular architecture of the heart (Powell 2006, Mearini 
et al 2008). Studies indicate that down-regulation of ubiquitin E3-ligases or 
UPS dysfunction may result in ischemic injury, cell death and the development 
of certain cardiomyopathies (Stöllberger et al 2002, Date et al 2005, Zolk et 
al 2006, Mearini et al 2008). In mice, the absence of pVHL in heart muscle has 
been shown to cause lipid accumulation, myofibrillar disorganization, cardiac 
muscle degeneration and the development of severe CHF (Lei et al 2008). How 
UPS dysfunction affects the progressive heart phenotype seen in MUL is yet to 
be enlightened.
7.6 Vascular abnormalities in MUL
Liver enlargement was obvious in half of the patients at the time of their di-
agnosis. Tumorous lesions of the liver, detected by US and MRI, were often 
present already in young MUL children, and 10% had liver lesions at the time 
of diagnosis (median age 2.1 years). These lesions were the most frequent tu-
mors encountered in MUL patients. They comprised of large blood-filled di-
lated hepatic sinusoids (hepatic peliosis) (Tsokos et al 2005, Iannaccone et al 
2006), which in the US follow-up tended to fluctuate in size and shape. This is 
in agreement with the fact that peliosis is associated with an increased pres-
sure in the hepatic circulation, caused by cardiac failure and pericardial con-
striction (Tsokos et al 2005). In MUL, liver enlargement is regarded as an early 
clinical sign of the heart disease. Interestingly, peliosis can also occur secondary 
to wasting illnesses, infections, organ transplantation, certain drugs, immuno-
logical deficiencies and diabetes mellitus or as a paraneoplastic phenomenon 
(Tsokos et al 2005, Iannaccone R et al 2006). Besides heart failure, diabetes and 
wasting are also typical for MUL.
Vascular anomalies in MUL were not restricted to the liver. Cystic blood vessels 
were seen in other organs as well, such as adrenal and thyroid glands, lymph 
nodes, kidneys, lungs and brain. These lesions stained extensively for the en-
dothelial marker CD34, which is expressed in both progenitor and mature en-
dothelial cells (Pusztaszeri et al 2006). The CD34 staining has been found to be 
negative in normal hepatic sinusoids but positive in liver malignancy (Haratake 
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et al 1990, Coston et al 2008), i.e. hepatocelluar carcinoma, highlighting an 
increased capillarization of the sinusoids (Dhillon et al 1992). Benign lesions 
may randomly show focal CD34 positivity, but the strong staining for CD34 
seen throughout the liver, as well as in the lymph nodes, in MUL is clearly 
abnormal and suggestive of a strongly disturbed angiogenesis (de Boer et al 
2000, Pusztaszeri et al 2006, Hes and Morreau 2009). The staining for α-SMA 
was also prominent, indicating that the lesions contained myocytes. HMB-45, 
the marker for PEComa was negative (Hornick et al 2006). The minimal staining 
for the proliferation marker MIB-1 was in agreement with the benign nature 
of the lesions. 
7.7 Ectopic tissues in MUL
Ectopic tissues and disturbed architecture were also present in other organ 
systems as well, indicating a defective control of cell migration. Both ovarian 
and adrenal tissues were found in the MUL kidneys. Ectopic or accessory adre-
nal tissues are usually found along the path of descent of the gonads but very 
rarely in kidneys (Lack et al 1997). The structure of the adrenal gland was also 
distorted in several MUL patients, showing fetal-type architecture, and mixing 
of cortical and medullar tissue. These findings, together with frequent gross 
organ anomalies, indicate disturbed organ development in MUL patients. The 
problem does not seem to be restricted to prenatal life, since several organs 
show progressive changes postnatally, such as hyperplasia of pancreatic islets, 
nodular hyperplasia of the adrenal gland and pericardial constriction. The mo-
lecular basis for the disturbed organogenesis remains to be fully elucidated.
7.8 Tumours in MUL
The results indicate that MUL is associated with an increased frequency of 
benign and malignant tumours and shows disturbed control of organ devel-
opment. Radiology and histopathological examinations revealed tumorous 
lesions in 76% of the subjects. The benign tumours included cysts, vascular ab-
normalities (peliosis), adrenal adenoma, parathyroid adenoma, thyroid goitre, 
pancreatic cystadenoma, renal angiomyolipoma, ovarian fibrothecoma and 
pheochromocytoma. Thirteen (15%) of the 89 MUL-patients had a malignant 
tumour, such as Wilms’ tumour, renal papillary carcinoma, thyroid papillary 
and medullar carcinoma, ovarian and endometrial carcinoma, acute lympho-
blastic leukemia, Langerhans cell histiocytosis and carcinoid tumour. 
Adrenal tumours have been described in rare genetic syndromes (Barlaskar et 
al 2007, Horvath et al 2008), such as the Li-Fraumeni cancer syndrome (LFS; 
OMIM 151623), which is caused by germline mutations of the tumour suppres-
sor gene p53 on chromosome 17q13 (Tabori et al 2008). The actions of p53 
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protein are known to be regulated by the UPS (Sun 2006). Adrenocortical tu-
mours have also been described in endocrine syndromes, such as multiple en-
docrine neoplasia type 1 (MEN1; OMIM 131100). Affected subjects with MEN1 
frequently show tumours in the endocrine pancreas, parathyroid, pituitary, 
thymic and thyroid gland. Adrenocortical adenomas or nodular hyperplasia is 
seen in 25-40% of subjects with MEN1 (Falchetti et al 2008, Horvath et al 2008). 
McCune-Albright syndrome (MAS; OMIM 174800), characterized by polyostotic 
fibrous dysplasia, café au lait skin lesions, precocious puberty and endocrine 
overfunction, and the overgrowth syndrome BWS are two other syndromes as-
sociated with adrenocortical neoplasia (Horvath et al 2008). Interestingly, both 
loss of heterozygosity of the 17q22-24 region and somatic mutations of the 
PRKAR1A gene located on 17q22-24 have been shown to occur in sporadic 
adrenocortical tumours (Bourdeau et al 2006). Also, inactivating mutations of 
the PRKAR1A, have been found to cause nodular adrenocortical hyperplasia 
and the multiple endocrine neoplasia syndrome Carney complex (CNC; OMIM 
160980), an autosomal dominantly inherited syndrome responsible mainly for 
spotty skin pigmentation, endocrine overactivity, cardiac myxomas and adren-
ocorticotropic hormone (ACTH) independent Cushing’s syndrome due to nodu-
lar adrenocortical changes (Bourdeau et al 2006, Horvath et al 2008). PRKAR1A 
and p53 are known genes on chromosome 17q participating in adrenocortical 
tumorgenesis (Bourdeau et al 2006, Sun 2006, Tabori et al 2008) and TRIM37 
could probably be added to this list. 
A growing number of cancer-associated proteins have been linked to the ubiq-
uitin proteasome pathway; for instance, in the overgrowth syndrome BWS 
down-regulation of TSSC5 is associated with Wilms’ tumour (Scott et al 2006, 
2008). TSSC5 encodes a RING-finger protein, RING105, acting as an ubiquitin 
E3-ligase (Sun 2006). The tumour suppressor gene BRCA1, located on chromo-
some 17q21, encodes for a RING finger protein BRCA1 with ubiquitin E3-ligase 
activity. Mutations in the RING finger have been shown to abolish its E3 ac-
tivity. Interestingly, inactivating mutations have frequently been reported in 
ovarian carcinoma (Paul 2008) and breast cancer (Hashizume et al 2001). The 
familial cancer syndrome VHL results from germline mutations of tumour sup-
pressor gene VHL located on chromosome 3p25-26 encoding for a tumour sup-
pressor protein pVHL with E3-ligase activity (Jung et al 2006). In VHL, HIF-1α 
is up-regulated due to loss of function of pVHL, leading to overexpression of 
vascular endothelial growth factor (VEGF) and erythropoietin (EPO), and even-
tually enhanced vascular growth (Jung et al 2006, Shehata et al 2008). The 
elevation of VEGF also increases the vascular permeability, causing oedema 
which is seen as multiple cysts in different organ systems in VHL (Jung et al 
2006, Shehata et al 2008). 
VHL and MUL share some histological and radiological features and both predis-
pose the patients to multiple cystic and vascular lesions, primarily in endocrine 
tissues (Tattersall et al 2002, Jung et al 2006, Shehata et al 2008). These two 
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conditions, however, have their own distinct characteristics. Hemangiomas of 
the cerebellum, spine and retina are pathognomonic lesions for VHL (Tattersall 
et al 2002, Shehata et al 2008), while vascular lesions in the liver rarely oc-
cur. Moreover, the most common malignant tumour in VHL is renal clear-cell 
carcinoma (Tattersall et al 2002, Jung et al 2006, Shehata et al 2008) and not 
papillary carcinoma or Wilms’ tumour, as in MUL. Although the tumour spec-
trum of VHL and MUL clearly differs, loss of TRIM37 seems to result in cellular 
effects resembling those of VHL, including enhanced angiogenesis, develop-
ment of multiple cysts and to some extent even tumour growth. Intriguingly, 
the pathogenetic mechanism in VHL could at least to some extent be applied 
to MUL as well; MUL patients have low oxygen pressure (pO2) in blood-gas 
analysis (Karlberg et al unpublished data), have a restrictive cardiopathy, and 
frequently need supplementary oxygen during stress and infections. Moreover 
MUL subjects have an increased mean cellular volume of red blood cells (MCV) 
due to reticulocytosis probably as a reactive response to hypoxia (Karlberg et al 
unpublished data). Whether the loss of TRIM37 causes overexpression of VEGF 
or triggers some other vascular growth promoting pathway, will hopefully be 
answered in ongoing studies.
The malignant tumours found in MUL do not show a clear recognizable spec-
trum as in classic cancer syndromes, such as VHL (Jung et al 2006, Shehata et 
al 2008). Also, the malignancies in MUL do not occur at an especially early age 
(Hes and Morreau 2009). For instance, Wilms’ tumours in MUL were detected 
at a median age of 2.5 years as is the case in sporadic tumours (Scott et al 2006, 
2008). The age of Wilms’ tumour diagnosis is typically closer to 1.0 years in syn-
dromes caused by mutations in the WT1 gene on chromosome 11p13 (Scott et 
al 2006, 2008). However, the incidence of Wilms’ tumour was clearly elevated 
in MUL (6.5%, 6/92) and somewhat equal to the risk presented in BWS (4-10%) 
(Scott et al 2006). In MUL, the malignancies do not display multicentricity or 
bilateralism as in classical cancer syndromes (Hes and Morreau 2009), but the 
benign tumours in MUL do. In addition to the two bilateral adrenocortical ad-
enomas, renal cysts were typically seen in both kidneys. Moreover, six females 
had a bilateral ovarian fibrothecoma and one female patient had an angiomy-
olipoma in one kidney and a hamartoma containing ovarian and adrenal tis-
sues and a metanephric adenoma in her other kidney. Also, one MUL patient 
was diagnosed with a thyroid adenoma in both lobes. 
Totally 232 tumorous lesions were detected in 70 of the 92 patients (76%). This 
shows that some MUL patients are not affected by tumour growth or have 
not simply been diagnosed with tumours, while some patients clearly present 
more than one tumour, which is typical for cancer syndromes (Hes and Morreau 
2009). There are many examples of genes responsible for cancer syndromes be-
ing defective in sporadic tumors with similar morphology and location (Jung et 
al 2006, Hemminki et al 2008, Karlberg et al 2009) and dysregulation of TRIM37 
has recently been implicated in the pathogenesis of sporadic fibrothecomas 
DISCUSSION
74
(Karlberg et al 2009). If Mulibrey nanism claims a place among established can-
cer syndromes remains to be seen.
7.9 Limitations of the study
Although our MUL patient cohort is the largest in the world, the major limita-
tion with this study is the small number of patients and their wide age range 
(0.7 to 77 years). Due to the small number of patients statistical analyses were a 
challenge and not always possible to carry out. Also, the possibility of statistical 
errors cannot totally be excluded due to small sample size. On the other hand, 
also clinically significant features failed to reach statistical significance. When 
assessing the glucose metabolism in MUL (II), age-, sex- and BMI-matched con-
trols would have been valuable and further increased the scientific impact. 
Also, a control group in the analysis of GH treatment in MUL (III) would have 
been valuable.
The diagnostic criteria presented are based on the Finnish patients and differ-
ent TRIM37 mutations may not result in the exact same phenotype. In particu-
lar, all patients reported outside of Finland have been notably compromised 
by the heart disease or had Wilms’ tumour. Presumably, while MUL is relatively 
well known to the Finnish pediatricians, it is elsewhere mainly recognized by 




Our results show that Finnish MUL patients with recessive mutations in TRIM37 
gene present a distinct clinical phenotype but clinical variation exists. Also dif-
ferent TRIM37 mutations may not lead to the precisely same phenotype. The 
diagnosis remains a challenge. However, in subjects born SGA, lacking postna-
tal catch up growth, and having poor weight gain, hepatomegaly, and char-
acteristic craniofacial features, MUL should be considered. Although rare, this 
condition might also underlie CHF, failure to thrive or Wilms’ tumour in ab-
sence of a clear characteristic dysmorphology. 
MUL patients are born SGA with immature features and display a continuous 
deceleration in both height and weight throughout infancy. Feeding difficul-
ties and pneumonias are frequent early life concerns. GH therapy improved 
prepubertal growth but the long-term impact on final height remained mod-
est. In MUL, a dramatic change in glucose metabolism occurs with advancing 
age. While the children have low fasting glucose and insulin levels, the vast 
majority of the adults are insulin resistant and develop a full-blown metabolic 
syndrome. Notably, the GH treated subjects remained leaner and had less fre-
quent metabolic concerns than the untreated individuals. Importantly, MUL 
patients display disturbed organogenesis and have a high frequency of benign 
adenomatous and vascular lesions, as well as malignant tumours detectable in 
several internal organs. Additionally, MUL patients displayed lipid accumula-
tion in both liver and pancreas.
The extensive phenotype of MUL including common human pathologies like 
type 2 diabetes and tumours, speaks for a central role of the TRIM37 protein 
in cellular functions, such as insulin signalling, proliferation, migration and an-
giogenesis. Elucidation of the underlying molecular biology in Mulibrey nan-
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